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Mesenchymal stem cells of different origins were shown to differentiate into
insulin producing cells under appropriate conditions. This study assessed the potential of
umbilical cord lining stem cells (CLSCs), Wharton’s jelly derived mesenchymal stem
cells (WJSCs), and adipose tissue derived mesenchymal stem cells (ADSCs) to
differentiate into islet-like cells.
The basic morphology, pluripotency markers, immunophenotyping surface
markers of mesenchymal stem cells, and possible marker of pancreatic progenitor cells,
nestin, and sox17 of stem cells derived from umbilical cord, Wharton’s jelly, and adipose
tissue were defined and described. We investigated the potential of WJSCs ,CLSCs and
ADSCs to differentiate into islet-like cells in vitro using a 3 stage differentiation protocol
which had successfully differentiated bone marrow derived mesenchymal stem cells into
glucose responsive insulin secreting pancreatic islet-like clusters as described by Sun et al.
(Sun, Chen et al. 2007).
Transcripts of glucagon, proprotein convertase 1/3, ISL-1, and Nkx6-1 were
consistently upregulated at the end of differentiation in CLSCs, WJSCs, and ADSCs.
Other markers such as insulin, proprotein convertase 2, somatostatin, Glut2 transporter,
glucokinase, pdx1, pax4, pax6, mafA, neuroD1, neurogenin3 were upregulated at
transcript level at the end of differentiation, but not in a consistent manner. The
differentiated islet-like clusters which were shown to express insulin at transcript level
also stained positively with dithizone, a zinc chelating agent that selectively stains insulin
producing cells. C-peptide was also detected by ELISA in one of the experiments.
xii
Furthermore, the protein expression of glucagon, another hormone known to be produced
by islets of Langerhans, was also verified by immunostaining.
ADSCs, WJSCs and CLSCs were subjected to the 7-day differentiation protocol
described by Chiou et al. to determine if a shorter period of differentiation could be
achieved (Chiou, Chen et al. 2011). The 7-day differentiation protocol contained defined
factors which were similar to the combination of factors of stage 2 and stage 3 of the 3-
stage differentiation protocol but the time required for differentiation was shorter.
CLSCs and ADSCs could not tolerate this recipe and the cells started to die.
Furthermore, the pancreatic lineage profile of these differentiated ADSCs and CLSCs
was not comparable to the differentiated clusters underwent 3-stage differentiation
protocol. Upregulation of expression of glucagon, somatostatin were not detected in
ADSCs and upregulation of expression of PC2, and somatostatin were not detected in
CLSCs that underwent 7-day differentiation protocol. WJSCs tolerated the protocol but
insulin expression was not detected at the end of differentiation.
In conclusion, Wharton’s Jelly derived-stem cells, cord lining stem cells and
adipose tissue derived stem cells have potential to differentiate into islet-like insulin
expressing cells in response to defined culture conditions. However, further optimization
is required to obtain consistent glucose responsive insulin secretion from these
differentiated cells.
xiii
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Chapter 1
Introduction and Literature Review

1Chapter 1 Introduction and Literature Review
1.1 Background
1.1.1 What is diabetes?
Diabetes is a metabolic disorder which results in abnormally high blood glucose
levels and impaired glucose tolerance. Based on report of International Diabetes
Federation in 2010, South East Asia region has the highest number of deaths due to
diabetes of all the regions in the world. An estimated 1.1 million adults are expected to
die from the diabetes-related causes, accounting for 14.3% of all deaths. Diabetes can
lead to serious complications like heart attack, stroke, high blood pressure, blindness,
kidney disease, neuropathy, amputation and premature death. However, it can be
controlled by monitoring of the blood glucose, blood pressure, and blood lipids of
individual.
Classification of diabetes often depends on the circumstances present at the time
of diagnosis, and many diabetic individuals do not easily fit into a single class.
(American_Diabetes_Association, 2004a). For example, a person with gestational
diabetes mellitus (GDM) may continue to be hyperglycemic after delivery and may be
determined to have Type 2 diabetes. Therefore, for clinician and patient, it is less
important to label the particular type of diabetes than it is to understand the pathogenesis
of the hyperglycemia and to treat it effectively. Type 1 diabetes mellitus (T1DM) is the
autoimmune destruction of insulin producing beta cells of islet of Langerhans in pancreas
(Devendra, Liu et al. 2004). It will eventually lead to absolute insulin deficiency and
increased blood and urine glucose. Type 1 diabetes accounts for about 5-10% of those
with diabetes and develops most often in children and young adults but can appear at any
2age (American_Diabetes_Association, 2002). The symptoms of type 1 diabetes include
polyuria (frequent urination), polyphagia (increased hunger), polydipsia (increased thirst),
and weight loss (Cooke and Plotnick 2008).
T1DM commonly results from the autoimmune destruction of pancreatic beta
cells which involve the autoreactive T cells, CD4+ and CD 8+ T cells. The appearance of
a series of autoantibodies including islet cell antibodies (ICA), insulin autoantibodies
(IAA), auto-antibodies to the 65kD isoform of glutamic acid decarboxylase (GADA), the
protein tyrosine phosphotase-related IA-2 molecule (IA-2A) (Knip 2002). The zinc
transporter Slc30A8 residing in the insulin secretory granule of the beta cells (Wenzlau,
Juhl et al. 2007) was shown to be the first detectable sign of emerging beta-cell
autoimmunity. T1DM also has strong HLA associations, with linkage to the DQA and
DQB genes, and it is influenced by the DRB genes (Todd, Walker et al. 2007). These
HLA-DR/DQ alleles can be either predisposing or protective.
Type 2 diabetes is characterized by a relative insulin deficiency, reduced insulin
action, and insulin resistance of glucose transport in skeletal muscle and adipose tissue. It
is the most common form of the disease, accounting for 85-95% of all cases worldwide.
The risk of developing Type 2 diabetes increases with obesity, age, and lack of physical
activity. It occurs more frequently in women with prior gestational diabetes mellitus and
in individuals with hypertension. Most patients with Type 2 diabetes are obese, and
obesity itself is able to cause insulin resistance. They may have insulin levels that appear
normal or elevated, however, high blood glucose may lead to higher insulin levels which
overwhelm the secretory machinery of normal functional beta cells. Thus, insulin
secretion is defective and insufficient to compensate for insulin resistance. Insulin
3resistance may improve with weight reduction and drug treatment of hyperglycemia but it
is seldom restored to normal.
1.2 Currently available Diabetes Treatments
Patients with Type 1 Diabetes Mellitus (T1DM) are insulin dependent as a result
of autoimmune destruction of insulin producing beta cells of islet of Langerhans in
pancreas. Therefore, exogenous insulin therapy is required to improve the blood glucose
levels.
There are two types of insulin analogues whose structure has been altered to have
different pharmacokinetics properties to when compared to natural insulin available for
glycaemic control of diabetic patients. Rapid-acting insulin analogues are readily
absorbed from the injection site and thus act faster than natural insulin to supply the
insulin required after a meal. Long-acting insulin analogues are those released slowly
over a period of 8 to 24 hours, to supply the basal level of insulin for the day.
Multiple insulin injection (three or more injections per day) and continuous
subcutaneous insulin infusion are commonly used by diabetic patients for blood glucose
control to prevent long-term diabetes complications. Continuous subcutaneous insulin
infusion is used when patients fail to achieve good glycaemic control with conventional
injection regimes. It also led to the risk of more frequent and rapid onset ketotic episodes
whenever insulin delivery is interrupted. Besides, infections and inflammation at the
needle site may also affect the therapy (American_Diabetes_Association 2004b).
Other than the conventional subcutaneous and intravenous injection of insulin,
inhalation of insulin was also suggested to be a route for glycaemic control of diabetic
patients after meal. Inhalable insulin was available from September 2006 to October 2007
4in the United States as a new method of diabetes treatment. However, it was shown not to
work better than injected rapid acting insulin and the cost was much higher (Black,
Cummins et al. 2007). Furthermore, long-term safety and information on continued
efficacy had not been established (Owens, Zinman et al. 2003).
Treatment with exogenous insulin cannot ensure continuous control of blood
glucose levels and satisfactory prevention of complications. Therefore, alternative
treatments to substitute exogenous therapy of insulin have been explored. The major goal
of diabetic research is to find a functional substitute for the destroyed beta cells. The
more promising substitutes for the destroyed beta cells include whole-organ pancreas
transplantation and islet transplantation.
1.2.1 Whole organ pancreas transplantation
Pancreas transplantation involves implantation of a healthy pancreas into T1DM
patients. Most of the pancreas transplantation was done simultaneously in T1DM patients
who were undergoing kidney transplantation. Patients with co-transplantation of kidney
and pancreas were shown to have improved long-term survival compared to those
receiving only kidney transplantation (Bunnapradist, Cho et al. 2003). Co-transplantation
of kidney and pancreas also has positive effects on hyperglycemia (Kendall, Rooney et al.
1997), kidney transplantations (Fioretto, Steffes et al. 1998), and high blood pressure
(Elliott, Kapoor et al. 2001). However, patients with organs transplantation will need
intensive lifelong immunosuppressive therapy in order to keep their immune system from
rejecting the transplanted organs. Immunosuppressive therapy increases the risk for a
number of different kinds of infection and cancer. Therefore, only those whose potential
5benefit of the procedure is expected to offset the adverse effects of lifelong
immunosuppressive therapy will be considered. For example, this is only recommended
for patients with a history of severe metabolic complications, or consistent failure of
insulin-based management to prevent acute complications (Robertson, Davis et al. 2003).
Apart from the adverse effects of immunosuppressive therapy, the low availability of
pancreas organs also limits the number of pancreas transplant that can be performed
(Sutherland, Gruessner et al. 2004).
1.2.2 Human pancreatic islet transplantation
Although pancreas transplantation is relatively successful, the surgery is
complicated and associated with serious morbidity. Compared to pancreas transplantation,
human pancreatic islet transplantation is technically easier, has lower morbidity and
allows storage of the islet graft in tissue culture or cryopreservation for banking (Nanji
and Shapiro 2006). The success of human pancreatic islet transplantation using
Edmonton Protocol showed that insulin independence could be achieved for a median
duration of about 1t months could be achieved by selected patients suffering from T1DM
(Shapiro, Lakey et al. 2000). The Edmonton Protocol, which was named for the islet
transplantation group at the University of Alberta in Edmonton, Canada, is a method of
implantation of pancreatic islets for the treatment of type 1 diabetes mellitus. It involved
islets isolation from donor pancreas and followed by the infusion of isolated islets into
patients through portal vein under immunosupression. Recently it was reported that 70%
of the recipients showed insulin independence after transplantation (Alejandro, Barton et
al. 2008).
6However, pancreatic islet transplantation is still not sufficient for a permanent
cure of diabetes with long-term clinical benefit. Only 10% of the patients remained
insulin independent in a 5-year follow-up study after islet transplantation (Ryan, Paty et
al. 2005) and the average duration of insulin independence did not last for more than 15
months. Besides, large numbers of islets are required to achieve insulin independence and
the number of donor pancreas as a source of islets is limited. About 850,000 islets are
required to achieve insulin independence (Ryan, Lakey et al. 2002). As with pancreas
transplantation, the immunosuppressive therapy following islet transplantation also has
significant adverse effects. Therefore, there is still the need for further progress in the
availability of islets sources, maintaining islet function and reducing the adverse effects
of immunosuppressive therapy.
1.3 Gene Therapy
Recent reports suggested that insulin-producing cells derived from stem cells
could be a potential source for cellular therapy in diabetes. However, most of the stem
cells-derived insulin producing cells obtained from existing protocols did not show a
significant storage of insulin or a physiological regulation of insulin secretion. Several
groups had attempted to circumvent these hurdles by genetic manipulation to deliver
specific transcription factors or developmental control genes to stem cells or target tissues
to facilitate cell differentiation and/or to enhance the maturation process (Lavon, Yanuka
et al. 2006; Guo and Hebrok 2009).
71.3.1 In vitro gene therapy
Lavon et al. demonstrated that constitutive expression of Pdx-1 enhanced the
differentiation of human embryonic stem cells toward pancreatic endocrine and exocrine
cell types (Lavon, Yanuka et al. 2006). Pdx-1 expression also enhanced the expression of
several downstream transcription factors such as Ngn3, Pax4, Nkx2.2, and ISL-1.
Furthermore, Pdx-1 expressing mesenchymal stem cells were involved in regeneration of
pancreatic islets after transplantation of cells in STZ-induced diabetic mice. The Pdx-1
expressing mesenchymal cells were shown to differentiate into functional beta-cells after
treated with high concentration of glucose for 4 months (Tang, Cao et al. 2004). Several
other reports also demonstrated that Pdx-1 expression is crucial for endocrine neogenesis
in vitro (Jacquemin, Yoshitomi et al. 2006). As previously discussed, adult human bone
marrow-derived mesenchymal stem cells could be a potential source of insulin-producing
(Hess, Li et al. 2003; Zorina, Subbotin et al. 2003; Oh, Muzzonigro et al. 2004; Madec,
Mallone et al. 2009; Vija, Farge et al. 2009). It can be induced to differentiate into
functional insulin-producing cells when recombinant adenoviral vector carrying Pdx-1 is
introduced (Li, Zhang et al. 2007).
Other than introduction of Pdx1 into stem cells, recent report showed that over
expression of MafA in placenta-derived stem cells enhanced the insulin producing cells
differentiation (Chiou, Chen et al. 2011). The induced insulin producing cells were
shown to respond to glucose stimulation in vitro and rescue hyperglycemia when
transplanted to STZ-induced diabetic mice. Other than introduction of transcription
factors or developmental control genes, Chen et al. demonstrated a long-term correction
of diabetes in mouse through syngeneic transplantation of primary hepatocytes
8transduced with a glucose responsive promoter-regulated insulin transgene non-virally
(Chen, Sivalingam et al. 2005). Furthermore, autologous implantation of the primary
hepatocytes transduced with glucose responsive promoter-regulated insulin transgene
non-virally demonstrated the correction of porcine diabetes for about a year (Chen, Wong
et al. 2008).
1.3.2 In vivo gene therapy
Other than introducing therapeutic genes into the cells, direct administration of
the vector carrying genes of interest to the subjects might be an alternative because of its
simplicity and convenience. However, the work on safety and the efficiency of the
therapeutic gene carrying vector is still in progress. There are few strategies on in vivo
gene therapy, which involves delivery of gene of transcription factors that induce the
transdifferentiation into insulin-producing cells, genes carrying glucose-regulatable
insulin, and genes of the proteins that enhance glucose metabolism.
Over expression of Pdx-1 allowed reprogramming of rat hepatic stem cells into
functional insulin-producing cells (Li, Zhang et al. 2007). The delivery of lentivirus
carrying Pdx-1 gene into diabetic mice converted hepatic stem cells into pancreatic
endocrine precursor cells which were able to generate insulin-producing cells and rescue
hyperglycemia (Taniguchi, Yamato et al. 2003; Tang, Lu et al. 2006). Several other
reports also demonstrated that Pdx-1 expression is crucial for endocrine neogenesis in
vivo (Taniguchi, Yamato et al. 2003). Introduction of adenoviral vector carrying Pdx-1
activated the endogenous pdx-1 gene, and thus led to beta-cell neogenesis and ductal
proliferation. Another group demonstrated that NeuroD1 was most effective in enhancing
9insulin expression in primary duct cells after comparing the effects of expression of Pdx-
1, Ngn3, NeuroD1 or Pax-4 in duct cells. It showed that over expression of NeuroD1
induced the pancreatic progenitor cell differentiation into insulin-producing cells in
pancreas (Noguchi, Xu et al. 2006).
Zhou et al. demonstrated that the fully differentiated exocrine cells can be reprogrammed
into cells that closely resemble beta-cells in mice without reversion to a pluripotent stem
cell state by a combination of 3 transcription factors, Ngn3, Pdx1, and MafA (Zhou,
Brown et al. 2008). The reprogrammed cells expressed the essential genes for beta cell
function and could rescue hyperglycemia by remodeling local vasculature and secreting
insulin.
Other than introduction of genes of transcription factors, Ren et al. demonstrated
the long-term correction of diabetes in rat by direct administration of human insulin gene
carrying lentiviral vector to liver and thus induced partial liver-to-endocrine pancreas
transdifferentiation (Ren, O'Brien et al. 2007). The transdifferentiated liver demonstrated
the hepatic insulin storage in granules, and restoration of glucose tolerance. There were
also few reports on gene therapy that involved the delivery of insulin gene that have been
modified to make the proinsulin expressed susceptible to processing into mature insulin
(Dong and Woo 2001). A proteolytic cleavage site recognized by furin, a protease that is
present in many tissue including liver cells, was introduced into the proinsulin molecule
(Short, Okada et al. 1998; Auricchio, Gao et al. 2002). The most challenging part in using
insulin as a therapeutic gene is the glucose responsiveness to insulin transgene expression.
Different glucose-responsive promoters like promoter from the glucose-6-phosphatase
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gene (Chen, Meseck et al. 2001) and insulin gene allowed the minimal insulin transgene
regulation.
Several groups have reported the use of glucokinase gene to enhance glucose
metabolism and thus lower the blood glucose (O'Doherty, Lehman et al. 1999; Morral,
McEvoy et al. 2002). However, over-expression of glucokinase gene in liver may lead to
hyperlipidemia and fatty liver.
1.4 Stem cell therapy
Type 1 diabetes mellitus (T1DM) is the autoimmune destruction of insulin
producing beta cells of islet of Langerhans in pancreas. Therefore, one of the challenges
of stem cell therapy is to overcome the immune response, which means the autoimmunity
and rejection of allogeneic tissue. Hematopoietic stem cell is a cell isolated from the
blood or bone marrow. It may be a potential cell source for type 1 diabetes due to its
well-known immune suppression and anti-inflammatory properties (Haller, Viener et al.
2008; Trounson 2009). Voltarelli et al. demonstrated the modulation of the immune
response of the newly diagnosed type 1 diabetes patients after transplantation of
autologous nonmyeloablative hematopoietic stem cell (Voltarelli, Couri et al. 2007).
There were also few studies reported the use of autologous umbilical cord blood which
contains a huge population of immature, highly functional regulatory T cells with the
potential to restore the immune regulation as a source of immunomodulatory cells for the
treatment of type 1 diabetes mellitus (Ende, Chen et al. 2004; Haller, Wasserfall et al.
2009). These studies demonstrated the great potential of hematopoietic stem cells in the
treatment of newly diagnosed type 1 diabetes mellitus. However, in patients with long-
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standing type 1 diabetes, immunomodulation alone is not sufficient and should be
combined with insulin beta cell regeneration because of the autoimmune destruction of
insulin producing beta cells. Other than the immunomodulatory effect, stem cells with
high pluripotency also show the potential in generating a renewable source of insulin
producing cells.
Stem cells are cells with the ability to renew through mitotic cell division and
have the potential to develop into many different types of cells in the body. There are
three main types of stem cells: embryonic stem cells isolated from the inner cell mass of
blastocysts, neonatal stem cells isolated from umbilical cord, and adult stem cells or
progenitor cells that are found in the adult tissues. In embryo, stem cells can be
differentiated into all of the specialized embryonic tissues. In adults, progenitor cells and
stem cells act as a repair system, replenish specialized cells, and also maintain the normal
turnover of regenerative organs, such as blood, skin, or intestinal tissues. Given the high
plasticity of the stem cells, it showed the new potential for treating diseases such as
diabetes and heart disease. However, a lot of work remains to be done in the laboratory to
understand how to use these cells as a source for cellular therapy of the diseases.
1.4.1 Pancreas Development
Pancreas is a complex endoderm-derived organ consisting of exocrine and
endocrine glands. The exocrine gland is composed of secretory cells called acinar cells
that produce digestive enzymes that are secreted into small intestine through the
pancreatic ducts. The endocrine gland is composed of islets of Langerhans that maintain
proper glucose homeostasis. Each islet consists of five different endocrine cell types,
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each produces and secretes specific pancreatic hormones that are essential for the
regulation of glucose homeostasis in the blood: Alpha-cells (15%-30%) produce
glucagon, beta cells (50%-65%) produce insulin, delta cells (3%-5%) produce
somatostatin, PP-cells (~1%)secrete pancreatic polypeptide, and epsilon cells  produce
ghrelin (1%) (Gittes 2009; Kim, Miller et al. 2009).
Pancreas development is controlled by a complex interaction of signaling
pathways and transcription factors that determine early pancreatic specification and later
differentiation of exocrine and endocrine lineages. During development the three germ
layers, ectoderm, mesoderm, and endoderm, are generated at the stage of gastrulation
(Wells and Melton 1999). The gastrointestinal organs, including pancreas, are derived
from the definitive endoderm. Genes required for definitive endoderm formation include
wnt/betacatenin, Nodal, GATA4/6, and FoxA2 (Zorn and Wells 2007) and several
members of the Sox family including Sox17 (de Santa Barbara, van den Brink et al.
2003).
A number of signaling pathways including the Hedgehog, FGF, Notch, Wnt, and
TGF beta are also involved in beta cell proliferation and differentiation. Hedgehog
signals inhibit pancreas differentiation from the gut endoderm at the early stage.
Cyclopamine, a plant alkaloid that inhibits hedgehog signaling, is used to promote
pancreatic development in beta-cell differentiation (Kim and Melton 1998; Hart,
Papadopoulou et al. 2003). Notch signaling represses the development of both endocrine
and exocrine tissue (Hart, Papadopoulou et al. 2003). Wnt signaling participates in
pancreas development (Heller, Klein et al. 2003). In vitro, it was shown to be positively
regulated by Activin A (Xiao, Yuan et al. 2006) in differentiating embryonic stem cells
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into beta cells. TGF beta signal transduction is involved in the induction of definitive
endoderm. Both Nodal and Activin A are members of the TGF beta superfamily and are
essential for endoderm formation (Stainier 2002).
Pancreatic specification occurs around embryonic day (E8.5) in mouse. The
dorsal and ventral pancreatic buds merged to create the gland after the pancreatic
domains are specified and initiate morphogenetic budding (Jacquemin, Yoshitomi et al.
2006). Pancreatic epithelial cells proliferate, branch and differentiate into several types of
cells in the pancreas. Insulin and glucagon can be detected around E9.5. Pdx1 positive
cells give rise to exocrine, endocrine, and ductal cells implying that Pdx1 is a marker of
all pancreatic lineages.
Many transcription factors, such as Pdx1, Isl-1, Ngn3, Nkx2.2, Nkx6.1, NeuroD, Pax-4,
Pax-6, Rfx6, and MafA, have been identified as islet differentiation factors. Pdx1 is a
crucial transcription factors in pancreas formation (Offield, Jetton et al. 1996) and beta
cell differentiation (Sharma and Stein 1994). Isl-1 is required for the maturation,
proliferation and survival of the endocrine pancreas (Du, Hunter et al. 2009).
Neurogenin-3 (Ngn3) is essential for the development of the endocrine pancreas
(Gradwohl, Dierich et al. 2000). Pax-6 had been reported as an islet differentiation factor
and Pax-4 is essential for proper beta cell development (Sosa-Pineda, Chowdhury et al.
1997). Nkx2.2 is required for the final differentiation of beta cells and production of
insulin. Nkx6.1 acts as a beta cell determining factor. Smith et al. reported that Rfx-6
coordinated pancreatic islet development in vivo (Smith, Qu et al. 2010). Rfx-6 directed
the islet-cell differentiation downstream of Ngn3 and upstream of or in parallel with
NeuroD1, Pax4, and Arx transcription factors. The report showed that mice lacking Rfx-6
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failed in pancreas development. MafA is a basic-leucine zipper transcription factor that
controls beta cell specific expression of insulin gene (Olbrot, Rud et al. 2002). Activin A
was shown to be involved in the endocrine and exocrine lineage specification
(Scharfmann, Duvillie et al. 2008).
Figure 1 A schematic overview of the cell lineage determination during pancreas
development
1.4.2 Human Embryonic Stem Cells
Human embryonic stem cells are pluripotent cells derived from the inner mass of
the mammalian blastocyst. They proliferate indefinitely in an undifferentiated state and
can be induced to differentiate into cells of all three germ layers (Hoffman and Carpenter
2005). Embryonic cultures from mouse (Soria, Roche et al. 2000; Moritoh, Yamato et al.
2003; Blyszczuk, Asbrand et al. 2004; Li, Luo et al. 2009; Li, Lam et al. 2010) and
human (Van Hoof, D'Amour et al. 2009) were able to differentiate into insulin-positive
cells. Few groups reported that an ES cell that expresses nestin can be differentiated into
insulin expressing cells in vitro.
Nestin is an intermediate filament protein known to be a neural stem cells marker
(Lumelsky, Blondel et al. 2001; Hori, Rulifson et al. 2002).  The role of nestin expression
in insulin producing cells differentiation still remained to be elucidated. Two reports
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showed that the insulin expression of the cells derived from nestin-expressing cells was
not as a result of biosynthesis but from the uptake of exogenous insulin (Hansson,
Tonning et al. 2004; Sipione, Eshpeter et al. 2004). In addition, Wobus et al. showed that
the embryonic stem cells can differentiate into insulin-producing cells without selection
of nestin-expression (Blyszczuk, Asbrand et al. 2004). They managed to induce the
differentiation of unselected ES cells into islet-like clusters that express Pdx1, Pax4, and
insulin. The islet-like clusters showed the glucose responsiveness and beta-cell-specific
ion channel activity. When injected into streptozotocin induced diabetic
immunocompetent mice, reversal of diabetic condition was observed.
In 2006, D’Amour et al. developed a five-step protocol for differentiation of
human ES cells to endocrine cells capable of synthesizing the pancreatic hormones
insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin through their
understanding to fundamentals of normal embryonic development (D'Amour, Bang et al.
2006). The five-step protocols mimics in vivo pancreatic organogenesis by directing cells
through stages resembling definitive endoderm, primitive gut tube, posterior foregut,
pancreatic endoderm and endocrine precursor and finally hormone expressing endocrine
cells. In stage 1, ES cells were transitioned through mesendoderm to definitive endoderm
using high concentration of Activin A and adding Wnt3a during the first day of activin
exposure in the context of low FBS supplementation, as previously reported (Yamaguchi
2001; D'Amour, Agulnick et al. 2005). It was shown to express SOX17 and CXCR4, and
showed anterior character as indicated by expression of the anterior definitive endoderm
markers CER and FOXA2. In stage 2, FGF10 and the hedgehog-signaling inhibitor
KAAD-cyclopamine was added and activin A was removed, which is essential to allow
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the transition of definitive endoderm to a stage resembling the primitive gut tube.
Expression of the gut-tube markers HNF1B and HNF4A was found upregulated and the
expression of the definitive endoderm markers CER and CXCR4 was reduced. In stage 3,
the gut-tube endoderm was exposed to retinoic acid together with KAAD-cyclopamine
and FGF10. Upon addition of retinoic acid, the cells began to express high levels of PDX
and HNF6 while maintaining or increasing the expression of HNF1B and HNF4A, which
is the indicative of posterior foregut. In stage 4, the PDX1-expressing posterior foregut
endoderm cells were directed to the pancreatic and endocrine lineages. Through exposure
to DAPT and exendin 4, the cells expressed PDX1, NKX6-1, NKX2-2, Ngn3, and PAX4.
In stage 5, endocrine cells expressing the pancreatic hormones insulin, glucagon,
somatostatin, pancreatic polypeptide and ghrelin were produced after exposure to exendin
4, IGF1, and HGF. However, similar to fetal beta cells, the C-peptide secretion of the
cells responded to multiple secretory stimuli but not glucose, which implied that the
insulin expressing cells generated may be similar to immature fetal beta cells.  A crucial
limitation for embryonic stem cells is the tumorogenic potential of these cells. The high
plasticity of embryonic stem cells can give rise to teratomas and teratocarcinomas in
humans and therefore raises concerns about the safety of future clinical use of these cells
(Hori, Rulifson et al. 2002; Sipione, Eshpeter et al. 2004). Moreover, the ethical issues of
embryonic stem cells also restricted its use in stem cells research.
1.4.3 Induced Pluripotent Stem Cells (iPS) cells
In 2006, induced pluripotent stem cell was first described by Shinya Yamanaka's
group from Kyoto University in Japan (Takahashi and Yamanaka 2006). They used
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retroviruses to transduce mouse fibroblasts with the genes that had been identified as
important in embryonic stem cells. Eventually, four key genes required for the generation
of pluripotent stem cells were identified; Oct-3/4, SOX2, c-Myc, and Klf4. Soon after,
methods to reprogramme adult human cells to a pluripotent state were described (Okita,
Ichisaka et al. 2007; Yu, Vodyanik et al. 2007) and these methods were shown to be
applicable to a wide variety of adult cells (Park, Zhao et al. 2008). However, the use of
the oncogenes c-Myc and Klf4 raised concerns about potential tumor formation by
induced pluripotent cells. This concern has been addressed by the use of valproic acid, a
histone deacetylase inhibitor, which enables reprogramming of primary human
fibroblasts with only two factors, OCT4 and SOX2 (Huangfu, Osafune et al. 2008), thus
making the therapeutic use of reprogrammed cells safer and more practical.
The use of retroviral integration to introduce the genes raised the concerns about
the increased risk of insertional mutagenesis and tumorigenicity. Yamanaka’s group
reported the generation of induced pluripotent cells using repeated transfection of
expression plasmids and the induced pluripotent cells generated did not show evidence of
plasmid integration (Okita, Nakagawa et al. 2008).
The studies using induced pluripotent stem cells for insulin producing cells
differentiation was recently reported. Tateishi et al. demonstrated that skin fibroblast-
derived iPS cells can be differentiated into islet-like clusters through definitive and
pancreatic endoderm (Tateishi, He et al. 2008). Chen et al. also reported a highly efficient
approach to induce differentiation into insulin producing cells in a chemical-defined
culture system (Zhang, Jiang et al. 2009). The differentiated cells comprised nearly 25%
insulin-positive cells and were shown to respond to glucose stimulation comparable to
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adult human islets. These reports demonstrated that insulin-producing cells could be
generated from skin fibroblasts, suggesting that induced pluripotent cells derived from
patients could be a potential source of treatment for diabetes in future.
1.4.4 Mesenchymal stem cells
Mesenchymal stem cells are multipotent non-hematopoietic progenitor cells that
show the potential in treatment for autoimmune diseases because of their ability to
differentiate along different lineages in addition to the low immunogenic potential and
effects on immune response (Dazzi and Horwood 2007). Although no specific markers
has yet to be identified, mesenchymal stem cells expressing some cell surface antigens
like CD73, CD90, CD105, CD146, and CD200 have allowed them to be identified.
Mesenchymal stem cells were shown to differentiate into adipose, cartilage and bone
cells (Pittenger, Mackay et al. 1999), and produce some growth factors and cytokines like
IL-6, SCF, and VEGF which involved in cell signaling and immune response modulation
(Caplan and Dennis 2006). Type 1 diabetes mellitus is characterized by T-cell mediated
autoimmune destruction of pancreatic beta cells. Thus, the inhibitory effect of
mesenchymal stem cells on T cell proliferation and dendritic cell differentiation
suggested the potential of these cells as a source for treatment in diabetes.
1.4.4.1 Bone marrow derived mesenchymal stem cells
Rat bone marrow derived mesenchymal stem cells can be differentiated into
insulin producing cells in vitro using a high glucose culture medium (Oh, Muzzonigro et
al. 2004) or medium containing nicotinamide (Chen, Jiang et al. 2004). The differentiated
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cells showed islet-like morphology, expressed insulin at mRNA and protein levels, and
managed to control blood glucose level when transplanted into non-obese diabetic (NOD)
rats (Wu, Liu et al. 2007). Sun et al. demonstrated the differentiation of bone marrow
derived mesenchymal stem cells isolated from type 1 (n=5) and type 2 (n=5) diabetic
patients into insulin producing cells through a three-stage protocol (Sun, Chen et al.
2007). In the protocol, activin A, beta-cellulin and nicotinamide were included in a high-
glucose (25mM) medium to promote the differentiation. At the end of differentiation, the
islet-like cells showed high expression of Pdx-1, insulin and glucagon at mRNA level,
and secreted insulin in a dose-dependent manner in respond to glucose stimulation.
Transplantation of bone marrow derived mesenchymal stem cells was shown to
increase serum insulin levels and reduce blood glucose levels in streptozotocin-induced
diabetic mice (Hess, Li et al. 2003). Another group demonstrated that transplantation of
human bone marrow mesenchymal stem cells into streptozotocin-induced diabetic mice
enhanced insulin secretion and repair of pancreatic islets (Lee, Seo et al. 2006). Up to 3%
of the transplanted human mesenchymal stem cells engrafted into the pancreas, and up to
11% into the kidney. No cells were detected in lung, liver or spleen. The selectivity of
bone marrow derived mesenchymal stem cells for damaged tissues could be due to the
release of factors from damaged pancreas. In turn, the cytokines secreted by
mesenchymal stem cells were thought to create a tissue microenvironment that promoted
beta cell activation and survival.
1.4.4.2 Pancreatic Stem cells
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Some cells located in the adult pancreas are capable of differentiating into islet
cells after partial pancreatectomy. Islet cells differentiated from these stem cells might be
a potential source of treatment for diabetes (Guz, Nasir et al. 2001). Pancreatic stem cells
comprised of few populations, including islet-derived population of endocrine origin,
ductal epithelial and acinar cells of non-endocrine origin. Non endocrine stem cells are
mainly pancreatic ductal epithelial cells expressing the ductal markers, CK-19 and Pdx-1,
which shows the ability to differentiate into endocrine cells. Ramiya et al. first
demonstrated the generation of new islets from pancreatic ductal epithelial cells isolated
from prediabetic NOD mice (Ramiya, Maraist et al. 2000). These generated islets
contained alpha, beta and delta cells, responded to glucose stimulation, and reversed
diabetes after implanted into NOD mice.
Some other reports demonstrated the differentiation of pancreatic ductal epithelial
cells into insulin producing cells using differentiation medium containing some important
growth factors like activin A and hepatocytes growth factors or betacellulin (Mashima,
Ohnishi et al. 1996; Mashima, Shibata et al. 1996), GLP1 and exendin-4 (Zhou, Wang et
al. 1999). The differentiated insulin producing cells showed insulin expression at mRNA
levels, and secreted insulin in respond to glucose stimulation. Acinar cell is the most
abundant cell type in the pancreas and it has a common progenitor with islet cells (Gu,
Dubauskaite et al. 2002). Rooman et al. showed that dedifferentiation of primary rat
acinar cells in vitro has allowed the cells to gain embryonic and ductal characteristics like
expression of transcription factor Pdx1, neuroendocrine marker PGP9.5 and cytokeratins
CK-19 and CK-20 (Rooman, Heremans et al. 2000). Another report demonstrated the
differentiation of insulin producing cells from rat acinar cells with a combination of EGF
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and leukemia inhibitory factor in the culture medium. These differentiated cells expressed
characteristics of mature beta cells such as Pdx1, GLUT2 transporter, and insulin storage
granules and they were able to normalize hyperglycemia in diabetic mice (Baeyens, De
Breuck et al. 2005). These reports suggested that the pancreatic stem cells could be a
potential source of treatment for diabetes.
1.4.43.3 Amnion-derived stem cells
Amniotic derived stem cell is a new source of stem cells identified in a number of
extra-embryonic tissues including the placenta and chorion. It is an easy-to-obtain source
of stem cell which poses little or no ethical dilemmas compare to embryonic stem cells.
Amniotic derived stem cells exhibit the stem cell properties of long-term self-renewal,
pluripotency, low immunogenicity and anti-inflammatory effect. Previously, several
reports suggested the pluripotency of amniotic derived stem cells by demonstrating the
expression of stem cells markers like OCT-4, which is specifically expressed in ES cells,
GATA-4 and hepatocytes nuclear factor-3β, which expressed in definitive endoderm,
nestin, which is a neural stem cells-specific marker, and Nanog (Wei, Zhang et al. 2003;
Takashima, Ise et al. 2004; Miki, Lehmann et al. 2005). Hao et al. demonstrated the anti-
inflammatory effects of amnion derived stem cells by showing the expression of IL1
receptor antagonist; metalloproteinase TIMPs1, 2, 3, 4, and IL10 (Hao, Ma et al. 2000).
Akle’s study suggested the low immunogenicity and non-tumorigenicity of the cells
when amniotic membrane was transplanted into volunteers and there was no acute
rejection observed (Akle, Adinolfi et al. 1981). The advantages of amnion-derived stem
cells have attracted a lot of attention as a cell source for cell transplantation therapy.
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Currently there are only very few reports on differentiation of amnion-derived
stem cells into insulin producing cells. Wei et al. demonstrated the expression of insulin
at transcript level after culturing the amnion-derived stem cells with nicotinamide for 2 to
4 weeks (Wei, Zhang et al. 2003). When amnion derived stem cells was transplanted into
streptozotocin-induced diabetic mice, the blood glucose was normalized.
Immunohistochemistry suggested the integration of the cells into mouse tissue
differentiated into insulin producing cells by showing that antihuman-specific β-2-
microglobulin and anti-human-specific insulin located at the same place in mouse tissue.
This report suggested that the amnion-derived stem cells could be a potential source of
treatment for diabetes.
1.4.4.4 Adipose tissue derived stem cells
Human adipose tissue is available in large quantities as a waste product of
cosmetic liposuction, which involved a less invasive procedure than obtaining human
bone marrow. It had been reported that adipose tissue contains multipotent stem cells that
had the potential to differentiate into adipogenic, chondrogenic, osteogenic, myogenic,
neurogenic (Zuk, Zhu et al. 2001; Zuk, Zhu et al. 2002) endothelial (Planat-Benard,
Silvestre et al. 2004), hepatic (Seo, Suh et al. 2005; Timper, Seboek et al. 2006), and
pancreatic lineages (Timper, Seboek et al. 2006). Puissant et al. demonstrated the lack of
HLA-DR expression and immunosuppressive properties of adipose derived stem cells
(Puissant, Barreau et al. 2005).  This was further demonstrated by Fang et al., who
showed that severe refractory acute graft-versus-host disease (GVHD) could be treated
with human adipose-tissue-derived mesenchymal cells from HLA-mismatched donors
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(Fang, Li et al. 2010). The plasticity and immunomodulatory effect of adipose derived
mesenchymal stem cells suggested that it might be a potential stem cell source for future
clinical use.
There were only very few reports on differentiation of adipose derived
mesenchymal stem cells into insulin producing cells. One of the reports demonstrated the
differentiation of adipose tissue derived mesenchymal stem cells from healthy donors
into insulin, glucagon, and somatostatin expressing cells (Timper, Seboek et al. 2006).
During proliferation period, the cells expressed stem cell markers nestin, ABCG2, SCF,
Thy-1, and pancreatic endocrine transcription factor Isl-1. The cells were induced to
differentiate into pancreatic endocrine phenotype after 3 days incubation in high glucose
concentration medium containing activin, nicotinamide, exendin-4, hepatocytes growth
factor and pentagastrin. Insulin, somatostatin, and glucagon were shown to express at
mRNA level after 3 days induction.
In a recent report, adipose-derived mesenchymal stem cells was shown to
differentiate into insulin producing cells after 14 days incubation with pancreatic extract
from regenerating pancreas (Lee, Han et al. 2008). Pancreatic extract of regenerating
pancreas from rats after partial pancreatectomy was shown to initiate islet neogenesis and
rescue hyperglycemia in STZ-induced diabetic mice (Hardikar and Bhonde 1999).
Expression of some transcription factors related to beta cell development like FoxA2,
NeuroD, Hlxb9, and Nkx2.2 were observed at mRNA level at the end of differentiation.
C-peptide expression could only be detected in immunocytochemistry but not at
detectable level in differentiated cultures. One of the interesting reports demonstrated the
insulin producing cells differentiated from mesenchymal stem cells isolated from human
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eyelid adipose tissue directly regulated blood glucose levels in diabetic mice by releasing
human insulin (Kang, Kim et al. 2009). The isolated cells were differentiated into insulin
producing cells after a 2-stage differentiation protocol, including activin, nicotinamide,
and/or GLP-1in the high glucose concentration medium. The differentiated cells
normalized the hyperglycemia in 10 of 20 STZ-induced diabetic immunocompetent mice
after transplantation for two months. Therefore, the wide availability, plasticity, the
immunomodulatory effect of ADSCs had suggested that their potential for future clinical
use.
1.4.4.5 Human Wharton’s jelly-derived stem cells and Cord-lining stem cells
WJSC is a newly arising source of mesenchymal stem cells for cell therapy.
Wharton's jelly is the mucous connective tissue surrounding the two arteries and one vein
in the umbilical cord. The mesenchymal stem cells isolated from wharton’s jelly had been
reported to be multipotent and had the potential to differentiate into different cellular
lineage like adipose tissue, bone, cartilage, skeletal muscle cells, cardiomyocyte-like cells
and neural cells (Mitchell, Weiss et al. 2003; Gang, Jeong et al. 2006; De Coppi, Bartsch
et al. 2007). Fong et al. demonstrated that WJSCs expressed mesenchymal stem cell
markers CD44, CD90, and CD105 at high level and embryonic stem cell marker Tra-1-60,
Tra-1-81, and SSEA-4 at low level (Fong, Richards et al. 2007). Moreover, WJSCs did
not form tumors after injected into immunodeficient mice. These unique characteristics of
WJSCs suggested that they could be a potential stem cell source for future clinical use.
There were few reports on differentiation of WJSCs into insulin producing cells.
A recent report demonstrated the differentiation of WJSCs into islet-like cell clusters
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through a 4-stage induction protocol using a neuron-conditioned medium (Chao, Chao et
al. 2008). These islet-like cells expressed some pancreatic beta cell markers like Pdx-1,
Mnx1, Nkx2.2, Nkx6.1, and Glut2 at mRNA levels. Moreover, they were shown to have
C-peptide and secrete insulin in response to glucose stimulation. When transplanted into
streptozotocin-induced diabetic rat, hyperglycemia and glucose intolerance were
significantly improved. When compared to bone marrow derived stem cells, WJSCs have
higher pancreatic differentiation potential (Wu, Wang et al. 2009). The differentiated
WJSCs were shown to form larger islet-like clusters than bone marrow derived stem cells.
They were also shown to have higher expression of Pdx-1 and C-peptide at protein level
as compared to differentiated bone marrow derived stem cells. Wang et al. demonstrated
the curative potential of differentiated WJSCs via transplantation of cells into NOD mice
and normalize the glucose level (Wang, Shyu et al. 2011). These cumulative reports
suggested the potential of WJSCs to differentiate into insulin producing cells.
Recently, Prof. Phan Toan Thang from National University of Singapore
established the isolation of stem cells from the subamniotic region of the umbilical cord
and amniotic membrane (Kita, Gauglitz et al. 2010). Stem cells were derived from the
lining membrane of the umbilical cord after the blood vessels, intervascular and
perivascular parts of the Wharton’s jelly were removed. Several groups had demonstrated
the characterization of CLSCs (Ruetze, Gallinat et al. 2008; Kita, Gauglitz et al. 2010).
Reza et al showed that isolated CLSCs expressed embryonic stem cells markers including
Oct4, Nanog, Sox2, Rex1, and SSEA-4 (Reza, Ng et al. 2010). Zhou et al. demonstrated
the role of HLA-G in the immunoregulatory properties of CLSCs. When xeno-
transplanted into immunocompetent mice, CLSCs were shown to survive up to 14 days
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while the normal human keratinocytes were cleared within 48 hours. When two cells
were co-transplanted, CLSCs provided protection to human keratinocytes and prolonged
the survival of of keratinocytes significantly (Zhou, Gan et al. 2011).  Thus, this highly
proliferative, less immunogenic, non-tumorigenic, and ethically acceptable cell source
had shown its potential in cell-based therapy.
1.5 Objectives of the present study:
The objective of this study was to investigate the potential of WJSCs, CLSCs, and
ADSCs in differentiating into islet-like clusters.
Therefore, the aims of this study are:
A) To characterize the basic morphology, pluripotency markers, immunological
markers expression of mesenchymal stem cells, and markers of pancreatic
progenitor cells of stem cells derived from umbilical cord, Wharton’s jelly, and
adipose tissue.






Chapter 2 Materials and Methods
2.1 Materials
2.1.1 Primary cells and cell lines
2.1.1.1 Human Embryonic Kidney 293T cells
Human Embryonic Kidney 293T cells were purchased from American Type
Culture Collection (ATCC). HEK293T cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated FBS, 100units/ml
penicillin and 100ug/ml streptomycin at 37 °C under humidified air containing 5% CO2.
2.1.1.2 Cord lining stem cells
CLSCs were isolated by collaborator Associate Professor Phan Toan Thang and
other researchers from CellResearch Corp, Singapore, as described previously (Kita et al.
2010; Sivalingam et al. 2010) (international publication number WO 2006/019357 A1).
Human umbilical cords were collected with informed consent from mother after delivery.
Briefly, Wharton's jelly and blood vessels were dissected from the amniotic membrane.
The isolated amniotic membrane was cut into small pieces and explanted onto tissue
culture dishes. CLSCS were cultured in Medium 171 (Cascade Biologics) supplemented
with 50ng/ml insulin-like growth factor-1, 50ng/ml platelet-derived growth factor-BB,
5ng/ml transforming growth factor-β1, and 5ug/ml insulin (all from R&D Systems).
2.1.1.3 Wharton’s Jelly-derived mesenchymal stem cells
Wharton’s Jelly-derived mesenchymal stem cells (WJSCs) were isolated by
collaborator Assistant Professor Fong Chui Yee from the Department of Obstetrics and
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Gynaecology of National University of Singapore, as previously described (Fong et al.
2007). Umbilical cord was collected from patient after full-term delivery with patient
consent and Institutional Review Board (DSRB, National Healthcare Group) approval.
The umbilical cord was cut into pieces of 2 cm and placed with its inner surface facing
down in a Petri dish containing enzymatic solution which only allowed the Wharton’s
jelly to expose to the enzymes in order to loosen up the WJSC. The Wharton’s jelly
surrounding the umbilical cord blood vessels was gently detached into the DMEM
medium and the remaining cord pieces containing the vessels were discarded. The
DMEM medium containing the Wharton’s jelly was transferred to conical tubes and
centrifuged at 300 g for 5 min. The pellet was resuspended in hESC medium containing
high glucose DMEM, 20% FCS, L-glutamine, insulin–transferrin−selenium (ITS), basic
fibroblast growth factor (bFGF) and allowed to expand in tissue culture dishes.
2.1.1.4 Adipose tissue-derived mesenchymal stem cells
Adipose tissue-derived mesenchymal stem cells were isolated by collaborator Dr.
Kerrie Tang from Department of Orthopedic surgery. In brief, human adipose tissue was
digested with collagenase to isolate the stromal vascular fraction (SVF) and the SVF was
treated with NH4Cl to remove the red blood cells. The cell population with red blood
cells removed was termed a processed lipoaspirate (PLA), to distinguish it from the SVF
obtained from excised adipose tissue. PLA cells were maintained at 37°C/5% CO2 in
non-inductive culture medium: DMEM: F12 (1:1) containing 10% FCS, and 10ng/ml




Primers used for PCR experiment were designed using online program primer 3
(v. 0.4.0) (Rozen et al. 2000) at http://frodo.wi.mit.edu/primer3/ and primer-BLAST at
http://www.ncbi.nlm.nih.gov/tools/primer-blast/. Refseq mRNA sequences were
downloaded from NCBI sequence viewer. Most of the primer pairs were designed to
cross exons to eliminate the false positive results caused by genomic DNA contamination.
Primer sequences were also verified using BLAST to ensure specificity. NCBI reference
sequences nd primer sequences were listed in Table 1. The oligoneucleotides were





Forward Primer (5’ 3’) Reverse Primer (3’5’) Ampliconsize (bp)
Insulin NM_000207.2 TACCTAGTGTGCGGGGAAC GCTGGTAGAGGGAGCAGATG 196
Pdx1 NM_000209.3 GGATGAAGTCTACCAAAGCTCACGC ACATGACAGCCAGCTCCAC 185
Pax4 NM_006193.2 GTGGGCAGTATCCTGATTCAGT AGGTGGGGTGTCACTCAGAC 315
pax6 NM_000280.3 CCGGCAGAAGATTGTAGAGC TGGTATTCTCTCCCCCTCCT 487
NeuroD1 NM_002500.2 GACTATCACTGCTCAGGAC GCTTCTGCGTCTTAGAATAGC 453
Ngn3 NM_020999.3 TCCAAGTGACCCGTGAGAC GGGAGACTGGGGAGTAGAGG 501
MafA NM_201589.2 TTCAGCAAGGAGGAGGTCAT CGCCAGCTTCTCGTATTTCT 215
Glut2 NM_000340.1 CCCTTGGGCTGAGGAAGAGA AAGAATGCCCGTGACGATGG 367
PC1/3 NM_000439.4 TTGGCTGAAAGAGAACGGGATACATC ACTTCTTTGGTGATTGCTTTGGCGGTG 456
glucagon NM_002054.3 AGGCAGACCCACTCAGTGA AACAATGGCGACCTCTTCTG 308
Somatostatin NM_001048.3 TGCGCTGTCCATCGTCCT GCCATAGCCGGGTTTGAGTT 258
PC2 NM_002594.2 AAAGGAACCCCGAGGCCGGT CTTGGACGCCGGCTCAGCAA 544
Nkx6.1 NM_006168.2 GGCTCGTTTGGCCTATTCGT TCGTCGTCCTCTTCCTCGTT 177
Nkx2.2 NM_002509.2 CCTCCCCATCCCCAGTTTCT TGGAGCTTGAGTCCTGAGGG 494
ISL1 NM_002202.2 TGGTAGAGATGACGGGCCTC GGTTAGCCTGTAAGCCACCG 201
MafB NM_005461 TGTCAACGACTTCGACCTGC GTGTCTTCTGTTCGGTCGG 182
GCK NM_000162.3 CTGCAGGAGGAGGACCTGAA CAGGGGCAGCTTCTTGTGTT 366
β-actin NM_001101.3 GCTCGTCGTCGACAACGGCTC CAAACATGATCTGGGTCATCTTCTC 352
Nestin NM_006617.1 CAGGAGAAACAGGGCCTACA CTTCCCTCAGCTTTCAGGAC 180
Sox17 NM_022454.3 AGAATCCAGACCTGCACAAC ACCCGCTTCAGCCGCTTCA 187
Rfx6 NM_173560.2 ACCATCACGCAGATTGTGAA TTTGAATGGCCTCTTGTTCC 241
Table 1 Primers set used in RT-PCR
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2.1.3 Antibodies and assay kits
Anti-human CD44-RPE (BD Pharmingen)
Anti-human CD73-RPE (BD Pharmingen)
Anti-human CD90-FITC (Millipore)






FITC-conjugated goat anti rabbit IgG (Abcam)
HRP-conjugated swine anti rabbit IgG (DAKO)
Human C-peptide ELISA kit (Linco, Millipore)
Human GLP-1 ELISA kit (Linco, Millipore)
RNeasy mini kit (Qiagen)
RNase-free DNase set (Qiagen)
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2.2 Methods
2.2.1 In vitro differentiation towards insulin-producing cells
2.2.1.1 3-step differentiation protocol
Potential of in vitro differentiation of stem cells derived from different sources
(cord-lining stem cells, Wharton’s Jelly-derived mesenchymal stem cells, and adipose
tissue-derived mesenchymal stem cells) into insulin-producing cells was investigated
using a 3-stage differentiation protocol reported previously which was used to
differentiate bone marrow derived stem cells into insulin producing cells (SUN, Chen et
al. 2007 ). Stage 1: The cells were cultured for 2 days in serum-free high glucose DMEM
(25 mmol/L) (GIBCO, Invitrogen) containing 0.5 mmol/L β-mercaptoethanol (Sigma-
Aldrich). Stage 2: The cells then were cultured in the medium containing 1% non-
essential amino acids (Sigma-Aldrich), 20 ng/ml β-fibroblast growth factor (ProSpec), 20
ng/ml epidermal growth factor (ProSpec), 2% B27 (GIBCO, Invitrogen), 2 mmol/L L-
glutamine (GIBCO, Invitrogen) for 8 days. Stage 3: The cells were cultured for an
additional 8 days in medium containing 10 ng/ml β-cellulin (ProSpec), 10 ng/ml activin
A (ProSpec), 2% B27, 10 mmol/L nicotinamide (Sigma-Aldrich).
2.2.1.2 1-step 7-day differentiation protocol
Differentiation potential of WJSCs, CLSCs, and ADSCs into islet-like clusters
was assessed using a 7-day differentiation protocol described by Chiou et al. The
differentiation recipe contained 1% non-essential amino acids (Sigma-Aldrich), 20 ng/ml
β-fibroblast growth factor (ProSpec), 20 ng/ml epidermal growth factor (ProSpec), 2%
B27 (GIBCO, Invitrogen), 2 mmol/L L-glutamine (GIBCO, Invitrogen), 10 ng/ml β-
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cellulin (ProSpec), 10 ng/ml activin A (ProSpec), and 10 mmol/L nicotinamide (Sigma-
Aldrich).
2.2.2 Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cultured cells using Qiagen RNeasy Mini kit,
following the instructions of manufacturer. Samples were treated with DNase during
RNA extraction. RNA concentration was then measured using Nanodrop ND-1000
spectrophotometer. All the RNA samples were stored in -80oC and cDNA in -20 oC until
use.
Reverse transcription was done with SuperScript III First-Strand Synthesis
System (Invitrogen), using 0.5μg -2μg of total RNA primed with 2.5μM oligo dT (1st
base oligo, Singapore) for 1 hour at 50oC, with a reaction volume of 20μl. The reaction
was stopped by heating at 80oC for 5 mins.
PCR was done using Bio Rad Research PTC-100 Peltier Thermal Cycler, in a
total volume of 12.5μl with 0.5μl of RT product, 200μM of each dNTP (Promega),
0.4μM of each primer (1st base oligo, Singapore), 1.5mM MgCl2, 2.5μl 5x Green  GoTaq
Flexi Buffer and 0.625 units GoTaq Flexi DNA polymerase (Promega). PCR cycle
conditions were 45 secs at 95 oC, 30 secs at 58 oC, 30 secs at 72 oC, for 40 cycles, with
initial denaturation at 95 oC for 2 mins and final extension at 72 oC for 5 mins. β-actin
cDNA was used as a control and amplified with 25 cycles of PCR.
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2.2.3 Agarose gel electrophoresis
PCR products were identified by length using Agarose gel electrophoresis. 1%
Agarose gel was casted by dissolving 1mg of agarose into 100ml Tris-acetate-EDTA
(TAE) buffer using microwave heating. GelRedTM nucleic acid stain (Biotium) was added
and mixed well with the gel before pouring into the gel cast and left to set.
8μl of cDNA products from PCR was added into the wells. 1kb plus DNA ladder
(Invitrogen) was used as a reference to estimate the size of the PCR products. Gel
electrophoresis was done in TAE buffer in a horizontal gel system (Galelio Bioscience),
at 120 volts until bands of interest were properly separated.
Visualization of the bands was done on a UV transilluminator (Kodak) and
images were captured using KODAK 1D Image Analysis software (Kodak).
2.2.4 Flow cytometry
CLSCs, WJSCs, and ADSCs were harvested from tissue culture dishes using
Trypsin-EDTA and washed in 1xPBS. 5x105 cells were incubated with fluorophore-
conjugated antibodies (or the corresponding isotype control) in a volume of 55μl, for 2
hours at 4 oC. The cells were then washed and fixed with 2% Paraformaldehyde (PFA)
and analyzed on BD FACS CantoTM flow cytometer.
Flow cytometry data analysis was done using WinMDI software. A total of
30,000 events were acquired for each sample.
2.2.5 Enzyme-linked immunosorbent assay (ELISA)
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Culture supernatants were harvested from cells went through 3-stage
differentiation protocol and assayed for C-peptide using human C-peptide ELISA kit
(Linco, Millipore). ELISA was done following instruction of manufacturers and the
absorbance was measured at a wavelength of 450nm using VICTOR3™ V Multilabel
Counter model 1420 (PerkinElmer).
2.2.6 Cytospin
Cells were harvested from tissue culture dishes using Trypsin-EDTA. 3x105-
5x105 cells in 300μl of DMEM were loaded into each cytofunnel and spun at 1000rpm
for 7 mins to allow the cells to attach onto the poly-L-Lysine coated glass slides using
Shandon Cytospin 4 (Thermo Shandon). The cytospin slides were then air-dried and
ready for immunostaining.
2.2.7 Immunocytochemistry
Cytospin slides were fixed in 4% paraformaldehyde prior to immunostaining.
0.5% Triton-X was used for permeabilization. 10%goat serum was used as a blocking
agent to block non-specific binding sites in the cells. The slides were then immunostained
using anti-human sox17 (1:200 dilution) or anti-glucagon antibody (1:200 dilution)
(Abcams) followed by FITC or Texas Red-conjugated goat anti rabbit IgG (1:1000
dilution) prior for viewing under microscope.
2.2.8 Dithizone Staining
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Dithizone solution was prepared by dissolving 10mg of dithizone in 1ml of
DMSO. Cells of interest were then stained by adding 10ul of DTZ solution to cells in 1ml
of DMEM culture medium.
2.2.9 Microscopy
Microscopes were used for observing and imaging of experiments objects. Bright
field microscopy was used for cytospinned cells. Phase contrast microscopy was used for
observation of cultured cells along the differentiation. Confocal microscopy Olympus
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Chapter 3 Characterization of CLSCs, WJSCs, and ADSCs
3.1 Introduction
Mesenchymal stem cells are multipotent cells able to differentiate into multiple
lineages and have been recognized as a potentially useful therapeutic tool. However,
different isolation methods, culture conditions, and approaches to characterize the cells
may affect the selection of specific cell population with different potentials. Therefore,
the Mesenchymal and Tissue Stem Cell Committee of the International Society for
Cellular Therapy has proposed minimal criteria to define human mesenchymal stem cells
(Dominici, Le Blanc et al. 2006). First, MSC must be plastic-adherent when maintained
in standard culture conditions. Second, MSC must express CD73, CD90, CD105, and
lack expression of CD11b, CD14, D34, CD45, CD74 alpha, and HLA-DR surface
molecules. Third, MSC must be able to differentiate to osteoblasts, adipocytes, and
chondroblasts in vitro.
In this project, CLSCs, WJSCs, and ADSCs were chosen to assess the potential to
differentiate into islet-like cells. Basic morphology, pluripotency markers, immunological
markers expression of mesenchymal stem cells, and markers of pancreatic progenitor
cells, nestin, and sox17 of stem cells derived from umbilical cord, Wharton’s jelly, and
adipose tissue were defined and described.
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3.2 Results
3.2.1 Morphology of CLSCs
CLSCs isolated from different donors gave classical mesenchymal stem cells
morphology of adherent fibroblastic spindle-shaped cells in a monolayer culture. CLSCs
were sub-cultured with a ratio of 1:3 when confluent and were shown to have similar
morphology as cells of earlier passages after 16 passages (Fig. 3.1A, B).
Figure 3.1 Morphology of CLSCs
Passage 5    Passage 16
CLSC51
Passage 5    Passage 16
CLSC54
Phase contrast microscope view of CLSCs derived from different donor. (A) CLSC51 &
(B) CLSC54. (Magnification: 100x)
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3.2.2 Morphology of WJSCs
WJSCs isolated from different donors also showed classical mesenchymal stem
cells morphology of adherent fibroblastic spindle-shaped cells in a monolayer culture. It
displayed a homogeneous fibroblastic morphology (Fig. 3.2A, B). Similar to CLSCs,
WJSCs were sub-cultured with a ratio of 1:3 when confluent and were shown to have
similar morphology as cells of earlier passages after 16 passages.
Figure 3.2 Morphology of WJSCs
Passage 4    Passage 16
(A) Wharton’s Jelly derived stem cells, WJSC011m
Passage 5    Passage 16
(B) Wharton’s jelly derived stem cells, WJSC013f
Phase contrast microscope view of WJSCs derived from different donor. (A) WJ011m &
(B) WJ013f. (Magnification: 100x)
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3.2.3 Morphology of ADSCs
ADSCs also gave classical mesenchymal stem cells morphology of adherent
fibroblastic spindle-shaped cells in a monolayer culture. Adipose tissue derived stem cells
P200f appeared to be smaller (Fig. 3.3B) while P180f had a thin elongated appearance
(Fig.3.3A). ADSC is adult stem cell and has limited replicative potential compared to
WJSCs and CLSCs. It underwent replicative senescence characterized by cell
enlargement, and growth arrest after in vitro culture for a longer period. All ADSCs,
WJSCs, and CLSCs were isolated and maintained in different culture media.
Morphological differences suggested that the culture conditions affect the selection of
specific cell population with different potentials. Isolation of MSC is primarily based on
adherence of cells and growth under specific culture conditions. Therefore, culture media
and growth factors might play a significant role in the selection of specific cell
populations.
Figure 3.3 Morphology of ADSCs
(A) ADSCs, P180f, passage 5    (B) ADSCs, P200f, passage 5
Phase contrast microscope view of ADSCs derived from different donor. (A) P180f (B)
P200f. (Magnification: 100x)
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3.2.4 Fluorescence-activated cell sorting (FACS) analysis for MSC markers
Fluorescence-activated cell sorting (FACS) was performed on WJSCs of passage
5 from 3 different donors, CLSCs of passage 5 from 2 donors, and ADSCs of passage 4
from 1 donor using positive markers of human mesenchymal cells CD44, CD73, CD90,
and MHC class I and negative markers CD14, CD45 and MHC class II-DR to confirm
the mesenchymal features of the cells.
CD44 is a type of adhesion molecules which are typical of mesenchymal cells.
CD73 is a 5’-ectonucleotidase that converts 5’-adenosine monophosphate to adenosine,
which express on surface of mesenchymal cells. CD90 / Thy1 antigen is a GPI linked
glycoprotein member of the Immunoglobulin superfamily which expressed on
mesenchymal cells. CD14, CD45 and MHC class II are markers of hematopoietic stem
cell.
All cells characterized were positive for CD44, CD73, CD90, and MHC class I
and negative for CD14, CD45 and MHC class II-DR (Fig. 3.4A), which fulfilled the
minimum criteria to define mesenchymal stem cells proposed by the Mesenchymal and
Tissue Stem Cell Committee of the International Society for Cellular Therapy (Dominici,
Le Blanc et al. 2006).
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88% 97% 90% 95%
97% 94% 95% 93%
Figure 3.4 Expression of mesenchymal markers in WJSCs, CLSCs, and ADSCs
CD44    CD73        CD90 MHC Class I
CD14    CD45           MHC Class II-DR
(A) Cord lining stem cells, CLSC51
CD44     CD73       CD90 MHC Class I
CD14     CD45           MHC Class II-DR
(B) Cord lining stem cells, CLSC54
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99% 99% 95% 95%
100% 100% 30% 90%
CD44    CD73        CD90 MHC Class I
CD14    CD45 MHC Class II-DR
 (C) Wharton’s jelly derived stem cells, WJSC004m
CD44      CD73        CD90 MHC Class I
CD14     CD45          MHC Class II-DR
(D) Wharton’s jelly derived stem cells, WJSC011m
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99% 99% 93% 96%
100% 100% 99% 95%
CD44       CD73                    CD90            MHC Class I
    CD14            CD45          MHC Class II-DR
(E) Wharton’s jelly derived stem cells, WJSC013f
CD44  CD73               CD90             MHC Class I
CD14   CD45                     MHC Class II-DR
(F) Adipose tissue derived stem cells, P200f
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(G) Summary of MSC markers expression in CLSCs, WJSCs, and ADSCs. - indicated
negligible expression
FACS analysis of (A) CLSC51 (B) CLSC54 (C) WJSC004m (D) WJSC011m (E)
WJSC013f (F) P200f. Black color histograms represented isotype control staining. (G)
Summary of expression of mesenchymal markers in WJSCs, CLSCs and ADSCs.
CD44 CD73 CD90 MHC-Class I CD14 CD45 MHC-ClassII-DR
WJSC004m 99% 99% 95% 95% - - -
WJSC011m 100% 100% 30% 90% - - -
WJSC013f 99% 99% 93% 96% - - -
CLEC51 88% 97% 90% 95% - - -
CLEC54 97% 94% 95% 93% - - -
P200f 100% 100% 99% 95% - - -
45
3.2.5 Sox17 expression of WJSCs
Sox17, a member of the SOX (SRY-related HMG-box) family of transcription
factors, is involved in the control of development. It was expressed in primitive and
definitive endoderm and has been used as one of the markers of definitive endoderm
(Kanai-Azuma, Kanai et al. 2002; D'Amour, Agulnick et al. 2005).
RT-PCR analysis of Sox17 expression was performed on Wharton’s Jelly-derived
stem cells. Cord lining stem cells and adipose tissue derived stem cells were not included
because they were shown by our collaborators to have negative expression of Sox17
(personal communications, data not shown). The WJSCs screened gave strong expression
of Sox17 at transcript level (Fig.3.5A).
To verify the expression of Sox17 at protein level, WJSCW011m was stained





Wharton’s Jelly-derived Stem cells, WJSC004m, p13
Wharton’s Jelly-derived Stem cells, WJSC011m, p13
Wharton’s Jelly-derived Stem cells, WJSC011m, p3
Wharton’s Jelly-derived Stem cells, WJSC011m




(A) RT-PCR analysis of Sox17 expression in WJSCs. HepG2 was the positive control









(B) Sox17 expression in HEK293T, HepG2, and WJSC011m. 3 types of cells were
stained with anti-sox17 antibody. Red color indicated positive staining. Blue color
indicated Hoechsct 33342 nuclear counterstain.
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3.2.6 Nestin expression of CLSCs, WJSCs, and ADSCs
RT-PCR analysis of nestin expression was performed on cord-lining stem cells,
Wharton’s Jelly-derived stem cells, and adipose tissue derived stem cells. All the cells
gave strong expression of nestin at transcript level (Fig.3.6). Although the importance of
nestin in the development along the pancreatic lineage is still not well defined, the strong
expression of nestin in all three cell types from different sources suggested the potential




Wharton’s Jelly-derived Stem cells, WJSC013f
Wharton’s Jelly-derived Stem cells, WJSC011m
Cord-lining stem cells, CLSC54
Cord-lining stem cells, CLSC51
Figure 3.6 Nestin expression of WJSCs, CLSCs, and ADSCs
Nestin
β-actin
RT-PCR analysis of nestin expression in CLSCs, WJSCs, and ADSCs. β-actin was used
as loading control.
50
3.2.7 Nanog, Oct4, SOX2 expression of CLSCs, WJSCs, and ADSCs
RT-PCR analysis of Nanog, Oct4, and SOX2 expression was performed on
CLSCs, WJSCs and ADSCs. Expression of Nanog was expressed in all the samples
screened except CLSC51 of passage 5 and CLSC54 of passage 16 (Fig.3.7). Expression
of Oct4 was detected in CLSCs and WJSCs but not in ADSCs. Expression of Sox2 was
not detected consistently in stem cells derived from three different sources. Oct4, Nanog,
and Sox2 expression of ADSCs of passage 16 was not investigated because the cells have
limited replicative potential and were rarely sub-cultured for more than 14 passages.
Nanog is thought to play a critical role in regulating the cell fate of the pluripotent
inner cell mass during embryonic development, maintaining the pluripotent epiblast and
preventing differentiation to primitive endoderm (Chambers, Colby et al. 2003). Its
expression is restricted to pluripotent cells and is downregulated upon differentiation.
Oct 4 is a POU domain transcription factors plays a critical role in maintaining
embryonic cell pluripotency. Loss of pluripotency in embryonic stem cells is often
accompanied by downregulation of Oct4. Furthermore, Oct4 deficient mouse embryo
failed to develop beyond the blastocyst stage due to the lack of pluripotent inner cellular
mass (Nichols, Zevnik et al. 1998).
SRY (sex determining region Y)-box2 (SOX2) is a transcription factor essential
in maintaining self renewal of embryonic stem cells. It is thought to act as a
transcriptional activator after forming a protein complex with other proteins and thus
involved in the regulation of embryonic development and in the determination of cell fate.
Nanog, Oct4 and SOX2 are all key regulators of gene transcription in embryonic stem
cells. They have been reported to occupy the promoters of at least 2200 human genes and
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co-occupy 353 gene promoters (Boyer, Lee et al. 2005). Therefore, they regulate the
pluripotency and self renewal both jointly and individually in human embryonic stem
cells.
The results suggested that CLSCs, WJSCs, and ADSCs shared some of the
phenotypic characteristics of embryonic stem cells. Expression of these markers in
CLSCs and WJSCs of later passages also suggested that the potency of the cells might be
maintained even after a longer period in culture. These advantages are important
considerations for their use in cell therapy.
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RT-PCR analysis of Nanog, Oct4, and Sox2 expression in CLSCs, ADSCs, and WJSCs















Stem cells derived from umbilical cord, Wharton’s jelly, and adipose tissues have
the similar classical mesenchymal stem cells morphology of adherent fibroblastic
spindle-shaped cells. CLSCs and WJSCs were shown to have similar morphology as cells
of earlier passages after 16 passages.
The presence of mesenchymal surface markers CD44, CD73, CD90, and MHC
class-I and negative expression for hematopoietic stem cells surface markers CD14,
CD45, and MHC class-II-DR in CLSCs, WJSCs and ADSCs fulfilled the minimum
criteria proposed by the Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy to define mesenchymal stem cells.
WJSC was shown to have homogenous expression of Sox17 and suggested that it
may serve as a precursor of pancreatic endocrine cells.
CLSCs, WJSCs, and ADSCs analyzed gave strong expression of nestin at
transcript level and suggested the potential in differentiation along pancreatic lineage.
Expression of Nanog, and Oct4 were consistent in WJSCs and CLSCs of different
passages from different donors. Oct4 expression was not detected in ADSCs screened.
Sox2 expression was not detected consistently in stem cells derived from three different
sources. Expression of these markers in CLSCs and WJSCs of later passages suggested
that these cells possess a high capacity of self-renewal and thus provide sufficient cell
source for the use in cell therapy.
Chapter 4




Chapter 4 In Vitro Differentiation of Stem Cells Towards Islet-like Cells Using
the 3-step Differentiation Protocol
4.1 Introduction
Recent studies have demonstrated the feasibility of generating insulin-producing
islet-like clusters obtained from progenitor cells of various cellular sources. There were a
number of insulin producing cells differentiation protocols reported but most of them
were not reproducible. Sun et al. demonstrated the differentiation of human bone marrow
derived mesenchymal stem cells into pancreatic islet-like clusters in vitro using a 3 stage
differentiation protocol and the islet-like clusters were shown to secrete insulin in
response to different glucose concentration (Sun, Chen et al. 2007). This 3-stage
differentiation protocol was one of the insulin producing cells differentiation protocols
that were shown to be reproducible (Gabr et al, manuscript submitted).
In this project, the potential of WJSCs, CLSCs, and ADSCs to differentiate into
islet-like clusters in vitro using the 3 stage differentiation protocol described by Sun et al.
was assessed.
The expression of genes of hormones produced by islets of Langerhans (insulin,
glucagon, and somatostatin), enzyme required for prohormone processing (Prohormone
convertase 1/3, and prohormone convertase 2), proteins involved in glucose metabolism
(Glut2 glucose transporter, and glucokinase), and transcription factors along the
pancreatic differentiation pathway (Pdx-1, Neurogenin 3, NeuroD1, pax4, pax6, ISL-1,
Nkx6.1, Nkx2.2, and rfx6) of the cells before and after differentiation were compared.
Upregulation of glucagon was further confirmed by Real-time PCR analysis and the
expression of glucagon in differentiated cells were verified by immunostaining.
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To compare the reproducibility of the differentiation, WJSCs, CLSCs, and
ADSCs derived from 4 donors and also the cells of different passages from the same
donor were subjected to the 3 stage differentiation protocol and the pancreatic lineage
gene profiles were compared. Cells were sub-cultured at a ratio of 1:3 when confluent.
Furthermore, the expression of the pancreatic lineage markers at different stages of
differentiation were determined.
The supernatant of islet-like clusters at the end of differentiation was harvested
and C-peptide ELISA was performed to quantify the C-peptide produced at the end of
differentiation. The differentiated islet-like clusters were also stained with Dithizone, a
zinc chelating agent that selectively stains insulin producing cells.
Proglucagon is differentially processed in alpha cells of pancreas to give glucagon,
and in the L cells of the intestine to generate glucagon-like peptide GLP-1. Expression of
PC1/3 in the cells resulted in increased processing to GLP-1 (Dhanvantari and Brubaker
1998). Expression of PC2 in the cells increased the processing of proglucagon to
glucagon (Wideman, Covey et al. 2007). Upregulation of PC1/3 at the end of
differentiation suggested the possible processing of proglucagon to GLP-1. To verify the
expression of GLP-1 at protein level, supernatant of WJSCs at the end of differentiation
was collected and assayed using GLP-1 ELISA kit.
56
4.2 Results
4.2.1 Differentiation of CLSCs into islet-like cells
4.2.1.1 3-step differentiation protocol
To investigate the ability of CLSCs differentiating into islet-like cells, CLSCs
were subjected to the 3 stage differentiation procedure. CLSCs were typically adherent
spindle shape under stage 1 differentiation medium (Fig.4.1). These cells began to form
cellular aggregates and larger clusters under stage 2 induction medium containing B27,
FGF2, and EGF. However, under stage 3 medium supplemented with B27, nicotinamide,
activin and betacellulin, most of the attached clusters started to detach. There was only
very limited numbers of islet-like clusters left at the end of differentiation.
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Figure 4.1 Morphology of CLSCs at different stages of differentiation
Stage 1 Day 0 Stage 1 Day 2/Stage 2 Day 0
Stage 2 Day 3 Stage 2 Day 6
Stage 2 Day 10 Stage 3 Day 7
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4.2.1.2 Comparison of pancreatic lineage markers of CLSCs before and after
differentiation
RT-PCR analysis of 18 markers including transcription factors along the
differentiation pathway Pdx1, pax4, pax6, neuro-differentiation factor 1, neurogenin 3,
mafA, Nkx6-1, Nkx2-2, ISL1, mafB, Rfx6, pancreatic hormone insulin, glucagon,
somatostatin, prohormone convertase PC1/3, PC2, Glucose Transporter 2, and
glucokinase was performed on uninduced and differentiated cord-lining stem cells
CLSC54. Insulin expression was not detected in the differentiated CLSCs (Fig4.2).
NeuroD1, Nkx6-1, and Neurogenin3 were found upregulated in the differentiated cells.





Figure 4.2 Expression of pancreatic genes by uninduced and differentiated CLSCs
β-actin
Pancreatic gene expression in control and differentiated CLSCs. RT-PCR analysis for
expression of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafa, Glut2, PC1/3,
PC2, glucagon, somatostatin, nkx6-1, nkx2-2, ISL-1, mafB, glucokinase, and rfx6 in























4.2.1.3 Comparison of pancreatic lineage markers of differentiated CLSCs derived
from different donors
RT-PCR analysis was performed on differentiated CLSCs derived from different
donors. Expression of PC1/3, glucagon, mafA, and mafB were detected consistently and
insulin, Pdx-1, Pax4, Pax6, Glut2, Nkx2-2, Glucokinase, and Rfx6 were not detected in
the 4 samples analyzed (Fig.4.3). Expression of Nkx6-1 and ISL-1 were detected in 3 out
of 4 samples analyzed. Expression of somatostatin was detected in 1 sample at the end of
differentiation, PC2, in 2 out of 4 samples analyzed.
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Pancreatic gene expression in differentiated CLSCs from different donors. RT-PCR
analysis for expression of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafa, Glut2,
PC1/3, PC2, glucagon, somatostatin, nkx6-1, nkx2-2, ISL-1, mafB, glucokinase, and rfx6




















4.2.2 Differentiation of ADSCs into islet-like cells
4.2.2.1 3-step differentiation protocol
In this experiment, the potential of ADSCs to differentiate into islet-like cells
using the 3 step differentiation protocol was assessed. Undifferentiated ADSCs were also
typically adherent spindle shape (Fig. 4.4). Under stage 2 differentiation medium
containing B27, FGF2, and EGF, these spindle-like cells formed spheroids, named
adipospheres (Okura, Komoda et al. 2009). Some of the spheroids formed were floating
and not attached to the tissue culture-treated dish. FGF2 has growth promoting effect on
pancreatic epithelial cells reported as precursors of beta cells (Ogneva and Martinova
2002). At the final stage of differentiation, adipospheres were incubated with medium
containing B27, nicotinamide, activin and betacellulin to promote the maturation of
precursor cells into islet-like clusters. Nicotinamide was reported to increase the rate of
proinsulin biosynthesis, and thus insulin production due to formation of new beta cells
through differentiation (Otonkoski, Beattie et al. 1993). The spheroids formed at stage 2
started to attach under stage 3 medium. Although some the clusters started to spread out
after attach to the surface, most clusters remained aggregated at the end of differentiation.
Okura et al. suggested culturing the cells under floating condition during final stage of
differentiation to enhance the maturation of clusters into insulin producing cells (Okura,
Komoda et al. 2009).
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Figure 4.4 Morphology of ADSCs at different stages of differentiation
Stage 1 Day 0 Stage 1 Day 2/Stage 2 Day 0
Stage 2 Day 4 Stage 3 Day 0
Stage 3 Day 4 Stage 3 Day 7
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4.2.2.2 Comparison of pancreatic lineage markers of ADSCs before and after
differentiation
RT-PCR analysis of 18 markers including transcription factors along the
differentiation pathway Pdx1, pax4, pax6, neuro-differentiation factor 1, neurogenin 3,
mafA, Nkx6-1, Nkx2-2, ISL1, mafB, Rfx6, pancreatic hormone insulin, glucagon,
somatostatin, prohormone convertase PC1/3, PC2, Glucose Transporter 2, and
glucokinase was performed on uninduced and differentiated ADSC P200f. Weak
expression of insulin and pax6 was detected in uninduced and differentiated cells. PC1/3,
PC2, glucagon, and somatostatin were upregulated in the differentiated cells. However,
pdx1, NeuroD1, Neurogenin 3, Nkx2-2, ISL-1, glucokinase, and Glut2 expression was
not detected at the end of differentiation.
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Differentiated
Figure 4.5 Expression of pancreatic genes by uninduced and differentiated ADSCs
β-actin
Pancreatic genes expression in control and differentiated ADSCs. RT-PCR analysis for
expression of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafA, Glut2, PC1/3,
PC2, glucagon, somatostatin, nkx6-1, nkx2-2, ISL-1, mafB, glucokinase, and rfx6 in





















4.2.2.3 Comparison of pancreatic lineage markers of differentiated ADSCs derived
from different donors
RT-PCR analysis was performed on differentiated ADSCs derived from different
donors. Expression of PC1/3, PC2, glucagon, somatostatin, Nkx6-1, and mafB were
detected consistently and Pdx-1, Pax4, NeuroD1, Neurogenin 3, Glut2, Nkx2-2, and
Glucokinase were not detected at transcript level in samples screened. Expression of
Glut2 was downregulated at the end of differentiation. This trend was found consistently
in cells derived from all donors. Expression of insulin, ISL-1 and Rfx6 were detected,
although not in a very consistent manner. Expression of pax6 was detected in 3 out of 4
samples screened. Expression of Neurogenin 3, NeuroD1, and mafA in the samples might
be due to the genomic contamination.
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Pancreatic gene expression in differentiated ADSCs derived from different donors. RT-
PCR analysis for expression of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafa,
Glut2, PC1/3, PC2, glucagon, somatostatin, nkx6-1, nkx2-2, ISL-1, mafB, glucokinase,




















4.2.3 Differentiation of WJSCs into islet-like cells
4.2.3.1 3-step differentiation protocol
In this experiment, the potential of differentiation of WJSCs into islet-like cell
through this 3 stage differentiation protocol was investigated. Under phase contrast
microscope, undifferentiated WJSCs (stage 1) were typically adherent spindle shape
(Fig.4.7). These spindle-like cells became aggregates (stage 2), and some clusters formed
under Stage 2 differentiation medium containing B27, FGF2 and EGF. These cells
continued to differentiate and eventually resulted in larger clusters under stage 3 medium
supplemented with B27, nicotinamide, activin and betacellulin.
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Figure 4.7 Morphology of WJSCs at different stages of differentiation
Stage 1 Day 0 Stage 1 Day 2/Stage 2 Day 0
Stage 2 Day 3 Stage 2 Day 5
Stage 3 Day 3 Stage 3 Day 9
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4.2.3.2 Comparison of pancreatic lineage markers of WJSCs before and after
differentiation
RT-PCR analysis of 18 markers including transcription factors along the
differentiation pathway was performed. Pdx1, pax4, pax6, neuro-differentiation factor 1,
neurogenin 3, mafA, Nkx6-1, Nkx2-2, ISL1, mafB, Rfx6, pancreatic hormone insulin,
glucagon, somatostatin, prohormone convertase PC1/3, PC2, Glucose Transporter 2, and
glucokinase was performed on uninduced and differentiated Wharton’s Jelly derived stem
cells WJSC011m. Insulin, MafA and somatostatin expression were found in the cells
after differentiation (Fig4.8). Expression of insulin gene was further confirmed by DNA
sequencing of the RT-PCR products (Data not shown). Similar to other cell types
investigated, Glut2 expression was shut down after differentiation. Upregulation of PC1/3,
PC2, and glucagon were detected in the differentiated cells. Expression of Nkx6-1,
NeuroD1, ISL-1 were detected in both uninduced and differentiated cells.
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Differentiated
Figure 4.8 Expression of pancreatic genes by uninduced and differentiated WJSCs
β-actin
Pancreatic gene expression in control and differentiated WJSCs. RT-PCR analysis for
expression of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafa, Glut2, PC1/3,
PC2, glucagon, somatostatin, nkx6-1, nkx2-2, ISL-1, mafB, glucokinase, and rfx6 in





















4.2.3.3 Comparison of pancreatic lineage markers of differentiated WJSCs derived
from different donors
RT-PCR analysis was performed on differentiated WJSCs derived from different
donors. Expression of PC1/3, glucagon, Nkx6-1, ISL-1, and mafB were detected and
pdx1, glucokinase, Nkx2-2, and Rfx6 were not detected consistently at transcript level in
samples screened (Fig.4.9). Expression of Glut2 was downregulated at the end of
differentiation. This trend was found consistently in cells derived from all the donors.
Expression of Pax4, Pax6 and Pdx-1 were detected in 1 out of 4 samples screened.
Expression of mafA, NeuroD1, Ngn3, and insulin were detected in 2 out of 4 samples
analyzed. Expression of somatostatin and Nkx6-1 were detected in 3 out of 4 samples
analyzed.
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Pancreatic gene expression in differentiated WJSCs derived from different donors. RT-
PCR analysis for expression of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafa,
Glut2, PC1/3, PC2, glucagon, somatostatin, nkx6-1, nkx2-2, ISL-1, mafB, glucokinase,




















4.2.3.4 Reproducibility of differentiation of the WJSCs from the same donors
6 sets of experiments were performed independently on WJSCW011m using 3-
step differentiation protocol and the pancreatic genes expression were analyzed using
RT-PCR to determine the reproducibility of the differentiation. The WJSCs were
subcultured at ratio of 1:3 when confluent. Insulin expression (3/6) was detected in both
early (passage 4) and later (passage 8) passage WJSCs. Expression of glucagon, Ngn3,
mafA, Isl-1, mafB, prohormone convertase PC1/3 and PC2 were detected in most of the
differentiated cells (Fig.4.10). Expression of somatostatin and Nkx6-1 were detected in 4
out of 6 samples analyzed. Transcription factor pax6, and Rfx6, and Nkx2.2 were not
detected in all the cells screened. Several reports showed that expression of Pdx1 was
detected in the differentiated insulin-producing cells however there were only 1/6 of the
differentiated clusters expressed Pdx1. Pax4, Glut2 glucose transporter and glucokinase
expression were also detected only in 1/6 of the samples screened.
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Ins Pdx1 Pax4 Pax6 NeuroD Ngn3 MafA G2 PC1/3 PC2 GCG SST Nkx6.1 Nkx2.2 ISL1 MafB GCK Rfx6
WJ011m p4 √ x x x √ √ √ x √ √ √ √ √ x √ √ x x
WJ011M p4 √ √ × × √ √ × x √ √ √ x x x √ √ √ x
WJ011m p6 x x x x x √ √ x √ √ √ √ √ x √ √ x x
WJ011m p6 x x √ x x √ √ x √ √ √ √ √ x √ √ x x
WJ011m p8 √ √ x x x √ √ √ x x √ √ √ x x √ x x
WJ011m p8 x x x x x x √ x √ √ x x x x √ √ x x
3/6 2/6 1/6 0/6 2/6 5/6 5/6 1/6 5/6 5/6 5/6 4/6 4/6 0/6 5/6 6/6 1/6 0/6
Pancreatic gene expression in differentiated WJSC011m. RT-PCR analysis for expression
of insulin, pdx1, pax4, pax6, NeuroD1, Neurogenin3, mafa, Glut2, PC1/3, PC2, glucagon,





















4.2.4 Expression of PC1/3, PC2, Glucagon and Somatostatin of CLSCs, ADSCs,
and WJSCs after differentiation
RT-PCR analysis was performed on uninduced and differentiated CLSCs, ADSCs,
and WJSCs and it showed the upregulation of PC1/3, PC2, glucagon, and somatostatin
expression in ADSCs and WJSCs at transcript level. PC1/3 and glucagon expression of
CLSCs did not show significant upregulation while the expression of PC2 and
somatostatin were shut down (Fig.4.11).
Proprotein convertase 1 (PC1/3) is an enzyme that performs the partial proteolytic
cleavage of prohormones. It plays a major role in the first step of biosynthesis of insulin.
Proprotein convertase 2 (PC2) is a serine protease responsible for the first step in the
maturation of many neuroendocrine peptides from their precursors. It plays a minor role
in the first step of insulin biosynthesis by converting proinsulin to insulin intermediates
and a greater role in first step of glucagon biosynthesis. Glucagon is a hormone
synthesized and secreted by alpha cells (α-cells) and somatostatin is a peptide hormone
secreted by delta cells of the mature islets of Langerhans. Therefore, upregulation of
these four genes suggested that the pancreatic lineage differentiation of the stem cells.
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Figure 4.11 PC1/3, PC2, glucagon, and somatostatin expression of uninduced and






Pancreatic gene expression in control and differentiated CLSCs, ADSCs and WJSCs. RT-
PCR analysis for expression of PC1/3, PC2, glucagon, and somatostatin in control and








4.2.5 Expression of Glut2, PC1/3, PC2, Glucagon and Somatostatin at different
stages along the 3-step differentiation pathway
RT-PCR analysis of Glut2, PC1/3, PC2, glucagon, and somatostatin was
performed on WJSCs at different stages of differentiation. PC1/3 and glucagon were
upregulated significantly at the end of stage 2 (Fig.4.12). Upregulation of PC2 was
detected only at the end of differentiation. Expression of somatostatin was detected at the
end of differentiation at transcript level. Glut2 expression was shown to shut down after
incubated in stage 2 medium for 8 days.
Nestin was reported to be a marker of early progenitor cells and expression was
down-regulated in all differentiated cells (Blyszczuk, Czyz et al. 2003; Kania, Blyszczuk
et al. 2003). In this experiment, nestin expression was slightly down-regulated at the end
of differentiation. This might be due to the incomplete differentiation of WJSCs. Insulin
expression was not detected at the end of differentiation (data not shown). The data
suggested that the 3-step protocol need to be further optimized for a more mature
differentiation.
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Figure 4.12 PC1/3, PC2, glucagon, and somatostatin, Glut2, and nestin expression of








Pancreatic gene expression of WJSC011m at different stages of differentiation along the
3-step differentiation protocol. RT-PCR analysis for expression of Glut2, PC1/3, PC2,
glucagon, and somatostatin of WJSC011m was performed. β-actin was used as loading
control.
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4.2.6 Real-time PCR analysis of expression of glucagon and PC1/3 of differentiated
WJSCs
Differentiated WJSCs was previously shown to have significant upregulation of
glucagon and PC1/3 at transcript level through semi-quantitative RT-PCR. Real-time
PCR analysis of glucagon and PC1/3 expression was performed by collaborators from the
Division of Regenerative Medicine, Pfizer, US on uninduced and differentiated WJSCs.
Glucagon expression of differentiated WJSCs was upregulated by 130 folds when
compared to uninduced WJSCs and PC1/3 was upregulated by 2896 folds (Fig.4.13). The
















Figure 4.13 Glucagon and PC1/3 expression of differentiated WJSCs
Fold increase of expression of glucagon and PC1/3 of differentiated WJSC011m when
compared to uninduced cells. Quantitative real time-PCR analysis for expression of
PC1/3 and glucagon of WJSC011m was performed.
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4.2.7 Dithizone staining of differentiated islet-like clusters
Insulin is synthesized from a precursor molecule, proinsulin. PC1, PC2, and
carboxypeptidase E cleaved the proinsulin into C-peptide, and the disulfide bonds
crosslinked peptide chains (A and B). The crosslinked peptides are the insulin monomer.
As the concentration of the protein increases, the monomers assemble into dimers and in
the presence of zinc, into hexameric crystals characterized by two Zn2+ atoms per
hexameric unit. It is this 2-Zn insulin hexamer that represents the active conformation of
the secreted hormone.
Dithizone, a zinc chelating agent was then applied for staining of zinc rich-insulin
producing cells (Shiroi, Yoshikawa et al. 2002). WJSCs, after 3-stage cell differentiation
gave strong positive staining of crimson red (Fig4.14A), indicating the presence of
insulin protein in the clusters. These cells were shown previously to express insulin at
transcript level (Fig.4.8). CLSC70 gave negative staining at the end of differentiation
(Fig.4.14B). These cells were previously shown not to have insulin expression at
transcript level (Fig.4.3). Thus, the results of DTZ staining correlated with PCR results.
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Figure 4.14 Dithizone staining of differentiated WJSCs and CLSCs
(A)
WJSCW011m, differentiated WJSCW011m, differentiated
(B)
CLSC70, differentiated
Dithizone staining of islet-like WJSC011m and CLSC70 cells after 3-stage insulin-
producing cell differentiation. The islet-like clusters were stained positively by dithizone
and showed crimson red.
84
4.2.8 C-peptide release of differentiated CLSCs, WJSCs, and ADSCs
C-peptide is the byproduct of proinsulin cleavage. Proinsulin was cleaved into c-
peptide and insulin during proinsulin processing by prohormone convertase 2. In this
experiment, supernatants of differentiated ADSCs, CLSCs, and WJSCs were collected
and assayed using C-peptide ELISA to quantify the release of C-peptide by differentiated
cells into media. C-peptide was detected by ELISA in only 1 of the 4 samples assayed
(Table 2). 0.74ng/ml of C-peptide was detected in the supernatant of differentiated
WJSCs.
Insulin expression at transcript level was detected in the differentiated WJSCs,
CLSCs and ADSCs assayed for C-peptide expression. However, C-peptide expression at
protein level was only detected in the differentiated WJSCs assayed but not ADSCs and
CLSCs. This might be due to the low expression of insulin of the cells and the level was
below the detection level of the kit. Further optimization of the differentiation protocol is
required for mature insulin producing cell.
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Table 2 C-peptide secretion of differentiated CLSCs, ADSCs, and WJSCs into
culture medium
Concentration of C-peptide in the medium of differentiated CLSCs, WJSCs, and ADSCs.
Stage 3 medium and uninduced CLSC54 were included as negative control. CLSC54
transduced with insulin gene was included as positive control.
Sample C-peptide concentration (ng/ml)
CLSC54, stage 3 day 8 0.00
WJSC011m, stage 3 day 8 0.74
ADSC, P119f, stage 3 day 8 0.00
ADSC, P170f, stage 3 day 8 0.00
Stage 3 Medium 0.00
CLSC54, uninduced 0.00
Insulin gene-transduced CLSC54 9.86
86
4.2.9 GLP-1 expression of differentiated WJSCs
Proglucagon is differentially processed in alpha cells of pancreas to give glucagon,
and in the L cells of the intestine to generate glicentin, oxyntomodulin, the incretin
glucagon-like peptide GLP-1, and intestinotropin GLP-2. Expression of PC1/3 in the
cells resulted in increased processing to glicentin, oxyntomodulin, GLP-1 and GLP-2
(Dhanvantari and Brubaker 1998). Expression of PC2 in the cells increased the
processing of proglucagon to glucagon (Wideman, Covey et al. 2007). RT-PCR analysis
demonstrated the upregulation of PC1/3 at transcript level at the end of differentiation.
Upregulation of PC1/3 suggested the possible processing of proglucagon to GLP-1. To
verify the expression of GLP-1 at protein level, supernatant of differentiated WJSCs was
collected and assayed using GLP-1 ELISA kit. No GLP-1 was detected in the supernatant.
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4.2.10 Glucagon immunostaining of uninduced and differentiated WJSCs
Glucagon expression of differentiated WJSCs was previously shown to have more
than 100 fold upregulation at transcript level when compared to uninduced WJSCs
(Fig.4.15). To verify the expression of glucagon at protein level, uninduced and
differentiated WJSCs were stained with anti-glucagon antibody. Expression of glucagon
was not detected in uninduced WJSCs (Fig.4.15A). Differentiated WJSCs were stained
for glucagon in a homogenous manner (Fig.4.15B). Glucagon expression was detected in
alpha cells of islets of Langerhans. The results suggested the differentiation of WJSCs
into glucagon expressing islet-like clusters.
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Glucagon expression in (A) uninduced and (B) differentiated WJSC011m. WJSCs
were stained with anti-glucagon antibody. Green color indicated positive staining.





In this chapter, the results showed the differentiation of WJSCs, CLSCs, and
WJSCs into islet-like clusters through the 3-stage differentiation protocol described by
Sun et al. CLSCs, WJSCs, and ADSCs were initially adherent spindle shape and started
to aggregate along the 3-stage differentiation and formed compact islet-like clusters at the
end of differentiation (Sun, Chen et al. 2007).
RT-PCR analysis showed that insulin expression was not detected consistently at
the end of differentiation regardless the type of cells used for differentiation.  Expression
of glucagon and PC1/3, the prohormone convertase required for proglucagon processing
were upregulated consistently at transcript level in all 3 cell types at the end of
differentiation. The results were further confirmed by real-time PCR analysis performed
which glucagon showed a 130-fold and PC1/3 showed a 2896-fold increase in
differentiated WJSCs. Glucagon expression at protein level was verified by
immunostaining. Expression of somatostatin, another hormone secreted by islets of
Langerhans, was uniquely upregulated in ADSCs when the cells were exposed to the 3
stage differentiation protocol. This was further confirmed by collaborators from Pfizer,
US through real time analysis (data not shown).
Glut2 glucose transporter and Glucokinase were required for glucose metabolism.
However, Glucokinase expression was rarely detected in differentiated clusters and Glut2
was initially expressed in uninduced CLSCs, WJSCs, and ADSCs and eventually shut
down after differentiation.
RT-PCR analysis also showed that similar pancreatic lineage profiles were
detected when CLSCs, WJSCs, and ADSCs isolated from different donors exposed to
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differentiation. Similar profiles were also detected when independent differentiation on
cells from the same donor (e.g. WJSCW011m) was carried out. The results demonstrated
the reproducibility of the differentiation.
Dithizone is a zinc chelating agent for staining of zinc rich-insulin producing cells.
Differentiated WJSCs which shown to express insulin at transcript level showed a
positive crimson red staining while the differentiate CLSCs with no insulin expression at
transcript level gave negative staining.
C-peptide was only detected in supernatant of 1 differentiated WJSCs through C-
peptide ELISA. C-peptide was rarely detected through ELISA although there was insulin
expression at transcript level. This might be due to the weak expression of insulin even at
transcript level in differentiated islet-like clusters.
Supernatant of differentiated cells was collected and assayed through ELISA to
detect GLP-1 expression but no GLP-1was detected. This was done because prohormone
convertase 1/3 involved in GLP-1 cleavage from proglucagon was upregulated at
transcript level in differentiated cells.
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Chapter 5 In vitro differentiation of stem cells towards islet-like cells using 1-step
7-day differentiation protocol
5.1 Introduction
Chiou et al. demonstrated one-step differentiation of placenta derived stem cells
into insulin producing cells that responded to glucose changes using a combination of
growth factors after transduction with transcription factor MafA (Chiou, Chen et al.
2011). The components of the defined factors of this 7-day differentiation protocol were
similar to the combination of factors of stage 2 and stage 3 of the 18-day 3-stage
differentiation protocol. Therefore, the differentiation of WJSCs, CLSCs, and ADSCs
through this protocol was carried out to determine if the differentiation could be achieved
through this 1-step 7-day protocol.
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5.2 Results
5.2.1 Islet-like cells differentiation of WJSCs, CLSCs, and ADSCs using 1-step 7-
day differentiation protocol
Chiou et al. reported the differentiation of placenta-derived stem cells into glucose
responsive insulin producing cells using a one step 7-day differentiation protocol with 7
defined factors in which the components were similar to the combination of factors of
stage 2 and stage 3 of the 18-day 3-stage differentiation protocol after transduction with
transcription factor MafA (Chiou, Chen et al. 2011).
In this experiment, WJSCs, CLSCs, and ADSCs were exposed to the
differentiation medium containing the combination of defined factors of stage 2 and stage
3 for 7 days. There was very limited number of CLSCs, WJSCs, and ADSCs aggregated
along the differentiation and very few clusters formed. The CLSCs and ADSCs started to
undergo cell death along the differentiation and there were only very limited numbers of
cells left at day 7 (Fig.5.1).
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Figure 5.1 Morphology of CLSCs, WJSCs, and ADSCs undergone 1-step
differentiation
(A) Cord-lining stem cells, CLSC54
Day 0    Day 3       Day 7
(B) Wharton’s jelly-derived stem cells, WJSC011m
Day 0    Day 3       Day 7
(C) Adipose tissue derived stem cells, P195f
Day 0    Day 3       Day 7
Morphology of (A) CLSCs (B) WJSCs and (C) ADSCs along the differentiation
94
5.2.2 PC1/3, PC2, glucagon, and somatostatin expression of uninduced and
differentiated CLSCs, ADSCs, and WJSCs
RT-PCR analysis of insulin, PC1/3, PC2, glucagon, and somatostatin was
performed on uninduced and differentiated CLSCs, ADSCs, and WJSCs at day 7. There
was no insulin expression after differentiation in all cells assessed (data not shown).
However, significant upregulation of PC1/3, PC2, glucagon, and somatostatin expression
was found in WJSCs (Fig.5.2). In CLSCs, PC1/3 was upregulated after differentiation.
However, expression of PC2 and somatostatin was downregulated after differentiation. In
ADSCs, there was no significant change in somatostatin expression and glucagon
expression was shut down after differentiation in 2 samples analyzed.
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Figure 5.2 PC1/3, PC2, glucagon and somatostatin expression of differentiated
WJSCs, ADSCs, and CLSCs
Pancreatic gene expression in control and differentiated CLSCs, ADSCs, and WJSCs.
RT-PCR analysis for expression of PC1/3, PC2, glucagon, and somatostatin in control
and differentiated CLSCs, ADSCs, and WJSCs. β-actin was used as loading control.




















ADSCs, WJSCs and CLSCs were subjected to the 7-day differentiation protocol
reported by Chiou et al.(Chiou, Chen et al. 2011) to determine if a shorter period of
differentiation could be achieved. However, there was only very limited of clusters
formed. Both CLSCs and ADSCs could not tolerate this protocol and started to undergo
significant cell death by day 7.
RT-PCR analysis on differentiated ADSC showed that there was no significant
upregulation of expression of glucagon, somatostatin, PC1/3, and PC2 which were
generally upregulated in differentiated clusters which underwent the 3-stage
differentiation protocol. Upregulation of these four genes were detected in differentiated






Chapter 6 Discussion and Conclusion
This study has studied the potential of umbilical cord lining stem cells (CLSCs),
Wharton’s jelly derived mesenchymal stem cells (WJSCs), and adipose tissue derived
mesenchymal stem cells (ADSCs) to differentiate into pancreatic islet-like cells using
published differentiation protocols (Sun, Chen et al. 2007; Chiou, Chen et al. 2011).
6.1 Characterization of WJSCs, CLSCs, and ADSCs
The initial part of the present study has characterized the basic morphology,
pluripotency markers, immunological markers expression of mesenchymal stem cells,
and possible marker of pancreatic progenitor cells, nestin, and sox17 of stem cells
derived from umbilical cord, Wharton’s jelly, and adipose tissue. WJSCs and CLSCs
showed typical mesenchymal morphology. They were adherent spindle-shape fibroblast
like and contained a large, round nucleus with a prominent nucleolus which was
surrounded by finely dispersed chromatin particles, giving the nucleus a clear appearance.
This is similar to the finding of Dominici et al. (Dominici, Le Blanc et al. 2006).
The study also demonstrated the presence of stemness markers Nanog, Oct4, and
Sox2 in CLSCs and WJSCs even after the cells were sub-cultured at a ratio of 1:3 when
confluent for 16 times. Fong et al. demonstrated the capability of WJSCs to differentiate
into neuronal lineage and Kita et al. reported the differentiation of CLSCs into adipogenic,
osteogenic, and chondrogenic lineage (Fong, Richards et al. 2007; Kita, Gauglitz et al.
2010). The high proliferation potential, easy availability from otherwise discarded tissue,
and plasticity of WJSCs and CLSCs ensure a sufficient and suitable starting source for
cell therapy.
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The present study confirmed that compared to WJSC and CLSC, ADSC is an
adult stem cell and has a relatively low replicative potential. The ADSC underwent
senescence after in vitro culture for 15 passages (data not shown). However, De Ugarte et
al. reported that ADSC has higher proliferation rate compared to bone marrow cells
obtained from the same donors (De Ugarte, Morizono et al. 2003). Furthermore, the
plasticity (Zuk, Zhu et al. 2001; Zuk, Zhu et al. 2002; Planat-Benard, Silvestre et al. 2004;
Seo, Suh et al. 2005; Timper, Seboek et al. 2006) and immunomodulatory effect of
ADSC suggested that there was still an important potential of ADSC as a stem cell source
for clinical use (Puissant, Barreau et al. 2005; Fang, Li et al. 2010).
The present study has investigated the expression of nestin in WJSCs, CLSCs,
and ADSCs. Expression of nestin was ubiquitously detected in WJSC, CLSC, and ADSC
cultures. The role of nestin in the development of pancreatic lineage has been a
controversial one. Hunziker et al. showed the nestin expression in cells located within
adult pancreatic islets (Hunziker and Stein 2000). These nestin-positive cells were
reported to be cultured ex vivo into different pancreatic cell types (Zulewski, Abraham et
al. 2001). Lumelsky et al. also reported that nestin-expressing embryonic stem cells can
differentiate into four endocrine cell types (Lumelsky, Blondel et al. 2001). Through
inhibiting the expression of nestin in embryonic stem cells and adult pancreatic duct stem
cells, Kim SY et al. demonstrated the role of nestin as an intermediate regulator in the
process of differentiation into insulin producing cells (Kim, Lee et al. 2010). Taken
together, nestin expression has been suggested to be crucial for differentiation of stem
cell into insulin producing cells.
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However, Treutelaar et al. reported that nestin-positive cells contribute to the
microvasculature but not endocrine cells of the islets (Treutelaar, Skidmore et al. 2003).
Delacour et al. demonstrated the consistent expression of nestin in pancreatic exocrine
cell lineage but not in endocrine progenitor cells (Delacour, Nepote et al. 2004).
Although the precise role of nestin in the pancreatic lineage remains to be elucidated, its
expression in CLSC, WJSC, and ADSC suggested the potential of these cells in
differentiation towards the endocrine lineage.
Nestin is a marker of early progenitor cells and the expression was reported to
down-regulate in the differentiated cells (Blyszczuk, Czyz et al. 2003; Kania, Blyszczuk
et al. 2003). However, Nestin expression of WJSCs was not down-regulated significantly
at the end of differentiation. This may suggest the incomplete differentiation in WJSCs,
or, only very small subpopulations of cells have fully differentiated. This observation
correlates with the sporadic expression of insulin transcript at the end of differentiation
found in my studies.
This study has also investigated the expression of Sox17 in stem cells derived
from 3 different sources. Expression of Sox17 was detected in WJSC but not in CLSC
and ADSC. Sox-17 is a transcription factor essential for endoderm formation (Hudson,
Clements et al. 1997; Clements, Friday et al. 1999). It was shown to express in
embryonic stem cells and be involved in endodermal organ differentiation and tissue-
specific gene expression (Qu, Pan et al. 2008). Expression of Sox17 was not detected in
CLSC. This might be due to the sub-culture medium of CLSC containing insulin-like
growth factor-1 and transforming growth factor-1 (Sivalingam, Krishnan et al. 2010).
Long-term exposure of CLSC to IGF-1 and TGF-β1 may push the cells toward a more
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mature phenotype and lead to the down-regulation of Sox17 in CLSC. It is not surprising
that Sox17 was absent in ADSC as it is an adult stem cells. A study reported by Kim et al.
also showed the expression of Sox17 in neonatal and fetal stem cells but not adult stem
cells (Kim, Saunders et al. 2007). The expression of Sox17 in WJSC suggested the
potential of WJSC to differentiate towards mature endodermal lineage such as pancreas.
6.2 In vitro differentiation of CLSCs, ADSCs, and WJSCs towards islet-like cells
using 3-step differentiation protocol
This project demonstrated differentiation of ADSCs, WJSCs, and CLSCs into
islet-like clusters using the 3-stage differentiation protocol described by Sun et al. (Sun,
Chen et al. 2007). There were many reports demonstrating the insulin-producing cell
differentiation from stem cells derived from different sources. However, most of the
protocols have not been followed up or repeated in other laboratories. Several
differentiation protocols reported were done on WJSCs, CLSCs and ADSCs but the
results showed limited or absence of differentiation along the pancreatic lineage (data not
shown). The 4-stage differentiation protocol described by Chao et al. (Chao, Chao et al.
2008) on WJSCs using a neuron-conditioned was done in the laboratory but the result
was not satisfactory. Chao et al. has reported the aggregation of cells along the
differentiation and eventually clusters formation. In contrast to the observation of Chao el
al., a monolayer of adherent cells were observed at the end of differentiation of WJSCs,
CLSCs, and ADSCs and the expression of insulin, Glut2 glucose transporter, and
pancreatic beta cell-related genes such as pdx-1, Nkx2-2, were not detected in my studies.
The protocol described by Sun et al. was successfully repeated by collaborator
using bone marrow derived stem cells (M Gabr, Mansoura, Egypt, personal
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communication). Therefore, in this study, this 3-stage differentiation protocol was
selected to assess the differentiation potential of WJSCs, CLSCs, and ADSCs. As
described by Sun et al., when exposed to the 3-stage differentiation, WJSCs, CLSCs, and
ADSCs with typical mesenchymal morphology started to aggregate at stage 2 and
eventually formed compact clusters at the end of stage 3. However, insulin expression at
transcript level was not detected consistently in the differentiated cells, and the
expression of insulin at protein level was detected in only 1 differentiated sample. The
bone-marrow derived stem cells used by Sun et al. and our collaborators were stem cells
isolated from bone marrow of type 2 diabetic patients. The long term exposure of the
cells to their pre-existing “diabetic environment” may be an important factor in favoring
insulin producing cell differentiation. To date, there is no published report on the direct
comparison of cells differentiated from diabetic versus non diabetic donors
In the present study, although insulin expression was not detected consistently at
transcript level in differentiated cells, expression of other hormones produced by islets of
Langerhans (glucagon and somatostatin) and the enzyme required for proinsulin and
proglucagon processing (PC1/3, and PC2) were generally upregulated at the end of
differentiation. These results suggested that the differentiated clusters were potentially
glucagon producing islet-like cells. Several reports showed that the differentiation
protocol available favored the differentiation of stem cells into glucagon producing cells
(Wilson, Wong et al. 2009; Rezania, Riedel et al. 2011). However, there was increasing
evidence suggesting that alpha cells exhibit a unique plasticity that allows the
transdifferentiation into insulin producing beta cells under certain conditions. Collumbat
et al. demonstrated the transdifferentiation of glucagon expressing alpha cells into insulin
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producing beta cells (Collombat, Xu et al. 2009). Ectopic expression of pax4 in the
mouse pancreas forced the endocrine precursor cells and mature alpha cells to
transdifferentiate into insulin producing cells. Furthermore, Thorel et al. reported that
near total beta cell ablation resulted in the conversion of pre-existing alpha cells to beta
cells (Thorel, Nepote et al. 2010).  In the light of these recent findings, the differentiated
glucagon-expressing cells created through the 3-step differentiation protocol may serve as
potential starting point for production of insulin producing cells.
The present study has shown the expression of Glut-2 transporter in uninduced
WJSCs and shut down by an unknown mechanism after exposure to stage 2
differentiation medium for 8 days. Glucokinase was rarely detected in differentiated cells.
Glut2 glucose transporter and glucokinase were shown to have strong expression in
human pancreas and are essential for glucose metabolism. The absence of the expression
of these two genes suggested that the differentiated clusters may not be able to secrete
insulin in response to glucose changes.
The present study showed that ISL-1 and Nkx6-1 were generally upregulated at
the end of differentiation but pdx-1, pax4, and pax6 did not show consistent expression in
the differentiated cells. Pdx-1, pax4, pax6, ISL-1 and Nkx6-1 are known to be found in
islets. The inconsistent expression of these factors in the differentiated cells may indicate
the incomplete islet-like cells differentiation.
This study has investigated the expression of GLP-1 in the differentiated cells.
Prohormone convertase 1/3 is involved in proglucagon cleavage into GLP-1 and
upregulation of PC1/3 in the differentiated cells may favor the GLP-1 formation. Wilson
et al. reported that some early mouse embryonic glucagon-expressing cells also expressed
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PC1/3 and thus likely to produce GLP-1 (Wilson, Kalamaras et al. 2002). However,
GLP-1 was not detected using ELISA after subjecting the CLSCs, WJSCs or ADSC to
the 3 stage protocol. This might be due to the cells were not directed to intestinal fate
along differentiation. Besides, dipeptidyl peptidase 4 (DPP-4) is an enzyme expressed on
the surface of most cell types and plays a major role in GLP-1 degradation. The ELISA
kit used was to detect the presence of bioactive GLP-1 but not the degraded GLP-1.
Presence of DPP-4 in the culture supernatant may lead to GLP-1 degradation resulting in
the failure to detect intact GLP-1.
In this project, C-peptide was assayed through ELISA to reflect the insulin
secretion of differentiated islet-like clusters to into the media instead of measuring insulin
available directly. The possible insulin uptake from surrounding media that lead to
detection of false-positive insulin secretion has been reported in studies of insulin
producing cell differentiation from embryonic stem cells (Hansson, Tonning et al. 2004;
Paek, Morgan et al. 2005). C-peptide is the by-product of proinsulin cleavage. Proinsulin
is cleaved into c-peptide and insulin during proinsulin processing by prohormone
convertase 2. Since C-peptide is co-secreted with insulin, concentration of C-peptide was
measured to reflect the insulin secretion in the media. Dithizone is a zinc-chelating agent
that selectively stains for insulin producing cells. The possible insulin uptake of cells
from media may lead to false positive results.
In this study, C-peptide was only detected in supernatant of 1 differentiated
sample. Although there was insulin expression at transcript level, C-peptide was rarely
detected through ELISA. This might be due to the low expression of insulin of the cells
and the level was below the detection level of the kit. This finding indicated that the 3-
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step differentiation protocol will require significant modification in the case of CLSCs,
WJSCs and ADSCs for them to produce insulin sufficient for treatment of diabetes.
6.3 In vitro differentiation of CLSCs, ADSCs, and WJSCs towards islet-like cells
using 1-step differentiation protocol
The present study also subjected ADSCs, WJSCs and CLSCs to the 1-step
differentiation protocol described by Chiou et al. to determine if a shorter period of
differentiation could be achieved. However, the result was not satisfactory as there were
only little clusters formed. Both CLSCs and ADSCs could not tolerate this protocol and
started to detach and die.
Furthermore, the pancreatic lineage profiles of these differentiated ADSCs and
CLSCs were not comparable to the differentiated clusters underwent 3-stage
differentiation protocol. Upregulation of expression of glucagon, somatostatin was not
detected in ADSCs and upregulation of expression of PC2, and somatostatin was not
detected in CLSCs underwent 7-day differentiation protocol. The results suggested that
the 7-day differentiation protocol was not suitable and further optimization will be
required.
6.4 Conclusion
In conclusion, this study has investigated the potential of WJSCs, CLSCs, and
ADSCs to differentiate into islet-like clusters. The 3-step differentiation protocol
described by Sun et al was shown to upregulate the expression of glucagon in WJSCs in a
consistent manner but not in CLSCs and ADSCs. However, expression of insulin was not
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detected in most of the differentiated islet-like clusters. Further optimization is required
for more consistent and mature islet-like clusters differentiation
6.5 Future work
Further studies that may improve insulin-producing cells differentiation would include:
1.  Transduction of genes of transcription factors such as Pdx-1, Neurogenin 3,
mafA, and NeuroD1 into stem cells prior to differentiation. Many reports have
demonstrated the insulin producing cells differentiation when the cells were pre-
transduced with genes of transcription factors prior to differentiation using a
combination of defined factors.
2. Expression of pax4 in alpha-cells has been shown to transdifferentiate glucagon
producing alpha cells into insulin producing cells. This thesis has demonstrated
the consistent upregulation of glucagon at transcript level. It would be interesting
to transduce the pax4 gene into the differentiated cells and study the effects.
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